Compounds > abt-737
Page last updated: 2024-11-12

abt-737

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11228183
CHEMBL ID376408
CHEBI ID47575
SCHEMBL ID158942
MeSH IDM0486083

Synonyms (46)

Synonym
abt 737
HY-50907
n3c ,
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]piperazin-1-yl}-n-{[4-({(1r)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl}amino)-3-nitrophenyl]sulfonyl}benzamide
n-benylpiperazine derivative, 2
4-(4-{[2-(4-chlorophenyl)phenyl]methyl}piperazin-1-yl)-n-[(4-{[(2r)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrobenzene)sulfonyl]benzamide
bdbm21447
chembl376408 ,
abt-737 ,
4-{4-[(4'-chlorobiphenyl-2-yl)methyl]piperazin-1-yl}-n-{[4-({(1r)-3-(dimethylamino)-1-[(phenylsulfanyl)methyl]propyl}amino)-3-nitrophenyl]sulfonyl}benzamide
2YXJ
852808-04-9
abt737
z5nfr173nv ,
unii-z5nfr173nv
4-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-n-[[4-[[(1r)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]benzamide
AKOS016003299
NCGC00253562-02
NCGC00253562-01
CS-0014
S1002
benzamide, 4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)-1-piperazinyl)-n-((4-(((1r)-3-(dimethylamino)-1-((phenylthio)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-
abt 737 [who-dd]
BRD-K56301217-001-01-7
benzamide, 4-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-n-[[4-[[(1r)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]-
AM81254
SCHEMBL158942
DTXSID7042641
compound 2 [pmid 17256834]
gtpl8320
4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4-dimethylamino-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide
(r)-4-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-n-((4-((4-(dimethylamino)-1-(phenylthio)butan-2-yl)amino)-3-nitrophenyl)sulfonyl)benzamide
EX-A056
mfcd12756212
SW218108-2
CHEBI:47575
4-{4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]piperazin-1-yl}-n-(4-{[(2r)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrobenzene-1-sulfonyl)benzamide
4-{4-[(4'-chloro[biphenyl]-2-yl)methyl]piperazin-1-yl}-n-[(4-{[(2r)-4-(dimethylamino)-1-(phenylsulfanyl)butan-2-yl]amino}-3-nitrophenyl)sulfonyl]benzamide
Q25105040
HPLNQCPCUACXLM-PGUFJCEWSA-N
4-(4-((4'-chloro-1,1'-biphenyl-2-yl)methyl)-1-piperazinyl)-n-((4-(((1r)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrophenyl)sulfony)benzamide
CCG-264769
nsc758873
nsc-758873
4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-n-[4-[[(2r)-4- (dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl] sulfonylbenzamide
BP-25381

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Our study shows that the combination therapy of immunotoxin plus ABT-737 is a promising approach for the future treatment of advanced prostate cancer to improve therapeutic efficacy and to reduce adverse side effects."( Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.
Kuckuck, I; Michalska, M; Noll, T; Schultze-Seemann, S; Wolf, P, 2018)		0.93

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analysis revealed that systemic DEX exposure in mice increased 2-fold when administered in combination with VCR and ASP, consistent with clinical findings, which may contribute to the observed synergy between the 3 drugs."( Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.
Boehm, I; Carol, H; Groepper, D; Kang, MH; Liem, NL; Lock, RB; Reynolds, CP; Stewart, CF; Szymanska, B; Wilczynska-Kalak, U, 2012)		0.38

Compound-Compound Interactions

ABT-737 potentiates the activity of agents that have inherent anti-lymphoma activity. Sorafenib, not alone but in combination with ABT- 737, efficiently induced apoptosis in hepatoma cells.

ExcerptReferenceRelevance
" ABT-737 was ineffective against Emu-myc/Mcl-1 and Emu-myc/A1 cells either as a single agent or in combination with HDACi."( Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors.
Alsop, AE; Banks, KM; Cluse, LA; Coomans, C; Johnstone, RW; Lindemann, RK; Newbold, A; Peart, MJ; Whitecross, KF; Wiegmans, A, 2009)		1.54
" Drug combination studies using a panel of conventional and novel therapeutic agents show that ABT-737 potentiates the activity of agents that have inherent anti-lymphoma activity and provide support for the evaluation of ABT-737 in the clinical setting."( Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737.
Daisley, L; Horton, T; Howard, SC; Jayanthan, A; Lewis, V; Narendran, A; Trippett, T; Whitlock, JA, 2009)		0.77
"We have previously shown that inhibition of translation initiation, using the small molecule inhibitor silvestrol, induces apoptosis in a pre-clinical murine lymphoma model when combined with daunorubicin."( Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells.
Carrier, M; Cencic, R; Minden, M; Pelletier, J; Porco, JA; Trnkus, A, 2010)		0.36
" Sorafenib, not alone but in combination with ABT-737, efficiently induced apoptosis in hepatoma cells."( The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Ishida, H; Iwase, K; Kanto, T; Kodama, T; Li, W; Miyagi, T; Shigekawa, M; Shimizu, S; Takehara, T; Tatsumi, T, 2010)		0.93
"Bcl-xL inactivation by ABT-737 in combination with sorafenib was found to be safe and effective for anti-HCC therapy in preclinical models."( The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Ishida, H; Iwase, K; Kanto, T; Kodama, T; Li, W; Miyagi, T; Shigekawa, M; Shimizu, S; Takehara, T; Tatsumi, T, 2010)		0.99
" HDACi were combined with ABT-737, which targets the intrinsic apoptosis pathway, recombinant human tumour necrosis factor-related apoptosis-inducing ligand (rhTRAIL/MD5-1), that activates the extrinsic apoptosis pathway or the DNA methyl transferase inhibitor 5-azacytidine."( Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
Atadja, P; Banks, KM; Bergsagel, PL; Chesi, M; Doyle, MA; Ellul, J; Faulkner, D; Johnstone, RW; Lefebure, M; Matthews, GM; Shortt, J; Vidacs, E, 2013)		0.92
" We examined the effects of the MDM2 inhibitor nutlin3a and its combination with the dual Bcl-2 and Bcl-xL inhibitor ABT-737, and the Bcr-Abl inhibitor nilotinib on BC CML patient samples."( Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Andreeff, M; Carter, BZ; Champlin, RE; Cortes, J; Kantarjian, HM; Konopleva, M; Mak, DH; Mak, PY; McQueen, T; Ruvolo, VR; Schober, W, 2015)		0.63
"To study the therapeutic effect of norcantharidin (NCTD) combined with ABT-737 on hepatocellular carcinoma cells and the molecular mechanism."( Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.
Li, G; Lin, L; Ren, J; Ye, T; Zhao, W, 2016)		0.96
" Liver cancer cells in the logarithmic phase of growth were vaccinated and cultured to the cell wall stage; these cells were treated for 48 h with different concentrations of NCTD, or ABT-737, or NCTD combined with ABT-737."( Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.
Li, G; Lin, L; Ren, J; Ye, T; Zhao, W, 2016)		0.92
"As the concentration of NCTD increased, the cell proliferation inhibition rate gradually decreased; and the treatment effect of ABT-737 1-3 μm combined with NCTD on cell proliferation inhibition was stronger than that of ABT-737 alone."( Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.
Li, G; Lin, L; Ren, J; Ye, T; Zhao, W, 2016)		0.93
"NCTD combined with ABT-737 has a positive role in the treatment of HCC, and it has great value in clinical research."( Norcantharidin combined with ABT-737 for hepatocellular carcinoma: Therapeutic effects and molecular mechanisms.
Li, G; Lin, L; Ren, J; Ye, T; Zhao, W, 2016)		1.05
" Since Pseudomonas Exotoxin A-based immunotoxins are known to preferentially inhibit the expression of the anti-apoptotic protein Mcl-1, the rationale was to test our immunotoxin in combination with the BH3 mimetic ABT-737, which specifically inhibits Bcl-2, Bcl-xl, and Bcl-w for enhanced induction of apoptosis in prostate cancer cells."( Synergistic cytotoxicity of a prostate cancer-specific immunotoxin in combination with the BH3 mimetic ABT-737.
Kuckuck, I; Michalska, M; Noll, T; Schultze-Seemann, S; Wolf, P, 2018)		0.88

Bioavailability

The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class, navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early clinical studies. However, ABT 737 is poorly soluble in aqueous conditions, and its orallyBioavailable derivative causes severe thrombocytopenia.

ExcerptReferenceRelevance
" However, ABT-737, a specific BCL2 inhibitor, is neither orally bioavailable nor metabolically stable."( Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.
Cohen, GM; Dyer, MJ; Furdas, SD; Jung, M; Kuwana, T; Vogler, M, 2010)		1
" Modification of ABT-263 may yield a BCL2 inhibitor with greater bioavailability and more favorable pharmacokinetics."( Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.
Cohen, GM; Dyer, MJ; Furdas, SD; Jung, M; Kuwana, T; Vogler, M, 2010)		0.6
"The BH3-mimetic ABT-737 and an orally bioavailable compound of the same class, navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early clinical studies."( Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Anderson, DJ; Belmont, LD; Bouillet, P; Campbell, KJ; Cory, S; Fairlie, WD; Glaser, SP; Huang, DC; Khaw, SL; Lee, EF; Ludlam, MJ; Mérino, D; Phipson, B; Robati, M; Roberts, AW; Vandenberg, CJ; Wong, C; Yue, P, 2012)		0.97
" The binding mode of the compounds was elucidated by X-ray crystallography, and the compounds showed excellent oral bioavailability and clearance in rat PK studies."( Lipophilic Isosteres of a π-π Stacking Interaction: New Inhibitors of the Bcl-2-Bak Protein-Protein Interaction.
Doré, M; Herlihy, K; Joud, C; Porter, D; Springer, C; Touré, BB; Visser, M; Xie, X; Yusuff, N, 2012)		0.38
" In this context, we reviewed the sometimes paradoxical antioxidant properties of quercetin and the functional role of its glucuronide and/or sulfate conjugates to discuss the low bioavailability of the molecule measured in vivo."( The pleiotropic flavonoid quercetin: from its metabolism to the inhibition of protein kinases in chronic lymphocytic leukemia.
Russo, GL; Russo, M; Spagnuolo, C, 2014)		0.4
" Taken together, our results suggest that inhibition of mitochondrial metabolism by Metformin or Phenformin is associated with increased leukemia cell susceptibility to induction of intrinsic apoptosis, and provide a rationale for clinical studies exploring the efficacy of combining biguanides with the orally bioavailable derivative of ABT-737, Venetoclax."( Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport.
Andreeff, M; Bornmann, W; Duque, JE; Enciso, L; Jaramillo, D; Konopleva, M; Krystal, G; Lee, JT; Lopez, C; Morales, L; Pan, R; Samudio, I; Suarez, M; Velez, J, 2016)		0.88
" Retrospective analysis of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compounds and improve the efficiency of drug design for future projects."( Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.
Chen, HJ; Cox, PB; DeGoey, DA; Wendt, MD, 2018)		0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
" However, ABT-737 is poorly soluble in aqueous conditions, and its orally bioavailable derivative causes severe thrombocytopenia."( Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.
Dang, MN; Day, ES; Scully, MA; Valcourt, DM, 2020)		1.2

Dosage Studied

ExcerptRelevanceReference
"The dose-response of multiple SCLC cell lines to actinomycin D in the absence and presence of ABT-737 was followed by the assessment of Bcl-2 family expression and poly ADP ribose polymerase cleavage by Western blot, viability by tetrazolium dye reduction and clonogenic assay, and cell cycle kinetics by flow cytometry."( Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines.
Krystal, GW; Xu, H, 2010)		0.81
" In platelets from mice dosed with ABT-263 in vivo, clopidogrel or deficiency of P2Y(12) receptor enhanced apoptosis along with increased Bak/Bax activation."( P2Y12 protects platelets from apoptosis via PI3k-dependent Bak/Bax inactivation.
Ding, Z; Kunapuli, SP; Liu, J; Xu, X; Ye, J; Zhang, S; Zhang, SH; Zhang, Y, 2013)		0.39
" The overall responses to anticancer agents and resulting pharmacological dose-response profiles were not affected by the growth of tumor cells in the presence DRAQ7."( Real-time cell viability assays using a new anthracycline derivative DRAQ7®.
Akagi, J; Darzynkiewicz, Z; Dobrucki, J; Errington, R; Kordon, M; Matuszek, A; Smith, PJ; Takeda, K; Wlodkowic, D; Zhao, H, 2013)		0.39
" Intrinsic resistance due to pre-existing cohorts of resistant cells precludes tumor regression, but dosing strategies that extend disease-free survival periods can still be identified."( Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas.
Byrne, HM; Jain, HV; Meyer-Hermann, M; Richardson, A, 2014)		0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
anti-allergic agentA drug used to treat allergic reactions.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
B-cell lymphoma 2 inhibitorAny inhibitor of B-cell lymphoma 2 protein.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (9)

ClassDescription
biphenylsBenzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
N-arylpiperazine
N-sulfonylcarboxamideA mixed diacylamine resulting from the formal condensation of the nitrogen of a carboxamide with a sulphonic acid.
aryl sulfideAny organic sulfide in which the sulfur is attached to at least one aromatic group.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency16.53880.00529.466132.9993AID1347411
EWS/FLI fusion proteinHomo sapiens (human)Potency11.44030.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
Interferon betaHomo sapiens (human)Potency16.53880.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Apoptosis regulator Bcl-XHomo sapiens (human)Ki0.00050.00050.00050.0005AID977610
Bcl-2-like protein 11Homo sapiens (human)IC50 (µMol)0.00200.00204.45168.9000AID515600
Apoptosis regulator Bcl-2Homo sapiens (human)IC50 (µMol)0.92780.00100.57634.3000AID1800239; AID1893747; AID1893748; AID587010; AID671073; AID675720; AID727591; AID756754
Apoptosis regulator Bcl-2Homo sapiens (human)Ki0.01820.00000.19012.9000AID1178314; AID1320544; AID1388438; AID1483462; AID1545355; AID1599454; AID1798080; AID1851856; AID277486; AID330776; AID389261; AID526646; AID640028; AID654461; AID675720; AID701527; AID710843; AID721471
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00030.00021.874210.0000AID515601
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00030.00031.09147.7625AID515601
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00030.00031.09147.7625AID515601
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00030.00031.06917.7625AID515601
Adenosine receptor A2aRattus norvegicus (Norway rat)IC50 (µMol)0.02000.00120.48289.0000AID727591
BH3-interacting domain death agonistHomo sapiens (human)IC50 (µMol)16.52430.02501.08673.0300AID1635029; AID515599
BH3-interacting domain death agonistHomo sapiens (human)Ki20.80000.20004.20008.6000AID1504724
Apoptosis regulator BAX Homo sapiens (human)IC50 (µMol)0.02300.02300.02300.0230AID515597
Bcl-2-like protein 1Homo sapiens (human)IC50 (µMol)0.92790.00031.04829.5400AID1194221; AID1580122; AID1635028; AID1800237; AID1800239; AID277496; AID462447; AID515597; AID515598; AID515599; AID515600; AID515601; AID587008; AID671072; AID675721; AID694152; AID756757; AID756759
Bcl-2-like protein 1Homo sapiens (human)Ki0.06440.00000.45819.0000AID1178313; AID1224377; AID1320545; AID1388439; AID1483463; AID1504723; AID1545356; AID1599455; AID1798080; AID1851857; AID277485; AID431401; AID526645; AID628395; AID628396; AID628397; AID628398; AID628399; AID628400; AID628401; AID628402; AID628403; AID628404; AID628484; AID628485; AID628486; AID628487; AID628488; AID640027; AID654462; AID675721; AID694152; AID701528; AID710850; AID756765
Induced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)IC50 (µMol)9.64540.00442.923510.0000AID1635029; AID1800237; AID1800239; AID587096; AID675722; AID683534; AID694153
Induced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)Ki28.80010.00101.46539.5400AID1178317; AID1224379; AID1320546; AID1483465; AID1504724; AID640029; AID654459
Aspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)IC50 (µMol)3.44000.02002.66099.4300AID1677972; AID1677973; AID1677974; AID1677975
Bcl-2-related protein A1Homo sapiens (human)Ki20.00001.47003.40005.3300AID1483466
Bcl-2 homologous antagonist/killerHomo sapiens (human)IC50 (µMol)16.68900.01000.03350.0570AID1635028; AID515598; AID683534
Bcl-2 homologous antagonist/killerHomo sapiens (human)Ki0.00100.00102.71829.0000AID1504723
Bcl-2-like protein 2Homo sapiens (human)IC50 (µMol)1.45730.00100.32512.3300AID1800239; AID587011; AID671074; AID756756
Bcl-2-like protein 2Homo sapiens (human)Ki0.05780.00101.25908.1900AID1178315; AID1483464; AID1545357; AID1599456; AID701526
Bcl2-associated agonist of cell death Homo sapiens (human)Ki0.00080.00050.15890.4900AID318565; AID389260
Bcl-2-binding component 3, isoforms 1/2Homo sapiens (human)IC50 (µMol)0.00030.00030.00030.0003AID515601
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Apoptosis regulator Bcl-2Homo sapiens (human)EC50 (µMol)0.14800.00300.13480.8500AID277489; AID277490; AID277491; AID277492; AID277493; AID277494; AID277497; AID277498; AID683531; AID701518
Apoptosis regulator Bcl-2Homo sapiens (human)Kd0.00060.00060.95874.8000AID727592
Bcl-2-like protein 1Homo sapiens (human)EC50 (µMol)0.02330.01000.03370.0650AID277499; AID539959; AID701519
Bcl-2-like protein 1Homo sapiens (human)Kd0.00020.00010.90252.8000AID587007; AID756752
Bcl-2 homologous antagonist/killerHomo sapiens (human)EC50 (µMol)0.02000.02000.02000.0200AID683531
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (332)

Processvia Protein(s)Taxonomy
intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 11Homo sapiens (human)
in utero embryonic developmentBcl-2-like protein 11Homo sapiens (human)
B cell homeostasisBcl-2-like protein 11Homo sapiens (human)
kidney developmentBcl-2-like protein 11Homo sapiens (human)
myeloid cell homeostasisBcl-2-like protein 11Homo sapiens (human)
apoptotic processBcl-2-like protein 11Homo sapiens (human)
cell-matrix adhesionBcl-2-like protein 11Homo sapiens (human)
spermatogenesisBcl-2-like protein 11Homo sapiens (human)
male gonad developmentBcl-2-like protein 11Homo sapiens (human)
post-embryonic developmentBcl-2-like protein 11Homo sapiens (human)
mammary gland developmentBcl-2-like protein 11Homo sapiens (human)
positive regulation of protein-containing complex assemblyBcl-2-like protein 11Homo sapiens (human)
response to endoplasmic reticulum stressBcl-2-like protein 11Homo sapiens (human)
tube formationBcl-2-like protein 11Homo sapiens (human)
odontogenesis of dentin-containing toothBcl-2-like protein 11Homo sapiens (human)
regulation of apoptotic processBcl-2-like protein 11Homo sapiens (human)
T cell homeostasisBcl-2-like protein 11Homo sapiens (human)
positive regulation of apoptotic processBcl-2-like protein 11Homo sapiens (human)
positive regulation of neuron apoptotic processBcl-2-like protein 11Homo sapiens (human)
ear developmentBcl-2-like protein 11Homo sapiens (human)
positive regulation of cell cycleBcl-2-like protein 11Homo sapiens (human)
regulation of organ growthBcl-2-like protein 11Homo sapiens (human)
developmental pigmentationBcl-2-like protein 11Homo sapiens (human)
regulation of developmental pigmentationBcl-2-like protein 11Homo sapiens (human)
spleen developmentBcl-2-like protein 11Homo sapiens (human)
thymus developmentBcl-2-like protein 11Homo sapiens (human)
positive regulation of T cell apoptotic processBcl-2-like protein 11Homo sapiens (human)
thymocyte apoptotic processBcl-2-like protein 11Homo sapiens (human)
cellular response to glucocorticoid stimulusBcl-2-like protein 11Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaBcl-2-like protein 11Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 11Homo sapiens (human)
positive regulation of mitochondrial membrane permeability involved in apoptotic processBcl-2-like protein 11Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayBcl-2-like protein 11Homo sapiens (human)
apoptotic process involved in embryonic digit morphogenesisBcl-2-like protein 11Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseBcl-2-like protein 11Homo sapiens (human)
positive regulation of fibroblast apoptotic processBcl-2-like protein 11Homo sapiens (human)
meiosis IBcl-2-like protein 11Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
regulation of blood pressureBeta-caseinBos taurus (cattle)
response to heatBeta-caseinBos taurus (cattle)
negative regulation of tumor necrosis factor-mediated signaling pathwayBeta-caseinBos taurus (cattle)
response to estradiolBeta-caseinBos taurus (cattle)
response to progesteroneBeta-caseinBos taurus (cattle)
negative regulation of canonical NF-kappaB signal transductionBeta-caseinBos taurus (cattle)
negative regulation of inflammatory responseBeta-caseinBos taurus (cattle)
cellular oxidant detoxificationBeta-caseinBos taurus (cattle)
negative regulation of lactationBeta-caseinBos taurus (cattle)
response to dehydroepiandrosteroneBeta-caseinBos taurus (cattle)
response to 11-deoxycorticosteroneBeta-caseinBos taurus (cattle)
negative regulation of cysteine-type endopeptidase activityBeta-caseinBos taurus (cattle)
protein polyubiquitinationApoptosis regulator Bcl-2Homo sapiens (human)
apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsApoptosis regulator Bcl-2Homo sapiens (human)
response to xenobiotic stimulusApoptosis regulator Bcl-2Homo sapiens (human)
response to toxic substanceApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of cell growthApoptosis regulator Bcl-2Homo sapiens (human)
response to cytokineApoptosis regulator Bcl-2Homo sapiens (human)
B cell proliferationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
regulation of calcium ion transportApoptosis regulator Bcl-2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandApoptosis regulator Bcl-2Homo sapiens (human)
G1/S transition of mitotic cell cycleApoptosis regulator Bcl-2Homo sapiens (human)
ossificationApoptosis regulator Bcl-2Homo sapiens (human)
ovarian follicle developmentApoptosis regulator Bcl-2Homo sapiens (human)
metanephros developmentApoptosis regulator Bcl-2Homo sapiens (human)
branching involved in ureteric bud morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
behavioral fear responseApoptosis regulator Bcl-2Homo sapiens (human)
B cell homeostasisApoptosis regulator Bcl-2Homo sapiens (human)
B cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
release of cytochrome c from mitochondriaApoptosis regulator Bcl-2Homo sapiens (human)
regulation of cell-matrix adhesionApoptosis regulator Bcl-2Homo sapiens (human)
lymphoid progenitor cell differentiationApoptosis regulator Bcl-2Homo sapiens (human)
B cell lineage commitmentApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of B cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
response to ischemiaApoptosis regulator Bcl-2Homo sapiens (human)
renal system processApoptosis regulator Bcl-2Homo sapiens (human)
melanin metabolic processApoptosis regulator Bcl-2Homo sapiens (human)
regulation of nitrogen utilizationApoptosis regulator Bcl-2Homo sapiens (human)
autophagyApoptosis regulator Bcl-2Homo sapiens (human)
humoral immune responseApoptosis regulator Bcl-2Homo sapiens (human)
DNA damage responseApoptosis regulator Bcl-2Homo sapiens (human)
actin filament organizationApoptosis regulator Bcl-2Homo sapiens (human)
axonogenesisApoptosis regulator Bcl-2Homo sapiens (human)
female pregnancyApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of cell population proliferationApoptosis regulator Bcl-2Homo sapiens (human)
male gonad developmentApoptosis regulator Bcl-2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressApoptosis regulator Bcl-2Homo sapiens (human)
response to radiationApoptosis regulator Bcl-2Homo sapiens (human)
response to xenobiotic stimulusApoptosis regulator Bcl-2Homo sapiens (human)
response to toxic substanceApoptosis regulator Bcl-2Homo sapiens (human)
post-embryonic developmentApoptosis regulator Bcl-2Homo sapiens (human)
response to iron ionApoptosis regulator Bcl-2Homo sapiens (human)
response to UV-BApoptosis regulator Bcl-2Homo sapiens (human)
response to gamma radiationApoptosis regulator Bcl-2Homo sapiens (human)
regulation of gene expressionApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of autophagyApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of calcium ion transport into cytosolApoptosis regulator Bcl-2Homo sapiens (human)
regulation of glycoprotein biosynthetic processApoptosis regulator Bcl-2Homo sapiens (human)
mesenchymal cell developmentApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of neuron maturationApoptosis regulator Bcl-2Homo sapiens (human)
smooth muscle cell migrationApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of smooth muscle cell migrationApoptosis regulator Bcl-2Homo sapiens (human)
cochlear nucleus developmentApoptosis regulator Bcl-2Homo sapiens (human)
gland morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
regulation of transmembrane transporter activityApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of ossificationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of cell growthApoptosis regulator Bcl-2Homo sapiens (human)
melanocyte differentiationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of cell migrationApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of B cell proliferationApoptosis regulator Bcl-2Homo sapiens (human)
hair follicle morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
axon regenerationApoptosis regulator Bcl-2Homo sapiens (human)
regulation of protein stabilityApoptosis regulator Bcl-2Homo sapiens (human)
endoplasmic reticulum calcium ion homeostasisApoptosis regulator Bcl-2Homo sapiens (human)
glomerulus developmentApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of cellular pH reductionApoptosis regulator Bcl-2Homo sapiens (human)
regulation of protein localizationApoptosis regulator Bcl-2Homo sapiens (human)
myeloid cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of myeloid cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
T cell differentiation in thymusApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationApoptosis regulator Bcl-2Homo sapiens (human)
osteoblast proliferationApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of osteoblast proliferationApoptosis regulator Bcl-2Homo sapiens (human)
response to nicotineApoptosis regulator Bcl-2Homo sapiens (human)
organ growthApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of multicellular organism growthApoptosis regulator Bcl-2Homo sapiens (human)
cellular response to glucose starvationApoptosis regulator Bcl-2Homo sapiens (human)
response to hydrogen peroxideApoptosis regulator Bcl-2Homo sapiens (human)
neuron maturationApoptosis regulator Bcl-2Homo sapiens (human)
T cell homeostasisApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
CD8-positive, alpha-beta T cell lineage commitmentApoptosis regulator Bcl-2Homo sapiens (human)
ear developmentApoptosis regulator Bcl-2Homo sapiens (human)
regulation of viral genome replicationApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of melanocyte differentiationApoptosis regulator Bcl-2Homo sapiens (human)
retinal cell programmed cell deathApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of retinal cell programmed cell deathApoptosis regulator Bcl-2Homo sapiens (human)
regulation of mitochondrial membrane permeabilityApoptosis regulator Bcl-2Homo sapiens (human)
focal adhesion assemblyApoptosis regulator Bcl-2Homo sapiens (human)
spleen developmentApoptosis regulator Bcl-2Homo sapiens (human)
thymus developmentApoptosis regulator Bcl-2Homo sapiens (human)
digestive tract morphogenesisApoptosis regulator Bcl-2Homo sapiens (human)
oocyte developmentApoptosis regulator Bcl-2Homo sapiens (human)
skeletal muscle fiber developmentApoptosis regulator Bcl-2Homo sapiens (human)
positive regulation of skeletal muscle fiber developmentApoptosis regulator Bcl-2Homo sapiens (human)
pigment granule organizationApoptosis regulator Bcl-2Homo sapiens (human)
stem cell developmentApoptosis regulator Bcl-2Homo sapiens (human)
homeostasis of number of cells within a tissueApoptosis regulator Bcl-2Homo sapiens (human)
B cell receptor signaling pathwayApoptosis regulator Bcl-2Homo sapiens (human)
response to glucocorticoidApoptosis regulator Bcl-2Homo sapiens (human)
neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
defense response to virusApoptosis regulator Bcl-2Homo sapiens (human)
establishment of localization in cellApoptosis regulator Bcl-2Homo sapiens (human)
regulation of mitochondrial membrane potentialApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of mitochondrial depolarizationApoptosis regulator Bcl-2Homo sapiens (human)
hematopoietic stem cell differentiationApoptosis regulator Bcl-2Homo sapiens (human)
calcium ion transport into cytosolApoptosis regulator Bcl-2Homo sapiens (human)
T cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of T cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
cellular response to organic substanceApoptosis regulator Bcl-2Homo sapiens (human)
cellular response to hypoxiaApoptosis regulator Bcl-2Homo sapiens (human)
reactive oxygen species metabolic processApoptosis regulator Bcl-2Homo sapiens (human)
dendritic cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
motor neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
cell-cell adhesionApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorApoptosis regulator Bcl-2Homo sapiens (human)
epithelial cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of epithelial cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of dendritic cell apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of motor neuron apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of anoikisApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of apoptotic signaling pathwayApoptosis regulator Bcl-2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayApoptosis regulator Bcl-2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageApoptosis regulator Bcl-2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandApoptosis regulator Bcl-2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processApoptosis regulator Bcl-2Homo sapiens (human)
release of cytochrome c from mitochondriaBH3-interacting domain death agonistHomo sapiens (human)
protein targeting to mitochondrionBH3-interacting domain death agonistHomo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of mitochondrial membrane potentialBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of protein-containing complex assemblyBH3-interacting domain death agonistHomo sapiens (human)
regulation of T cell proliferationBH3-interacting domain death agonistHomo sapiens (human)
signal transduction in response to DNA damageBH3-interacting domain death agonistHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of apoptotic processBH3-interacting domain death agonistHomo sapiens (human)
regulation of epithelial cell proliferationBH3-interacting domain death agonistHomo sapiens (human)
neuron apoptotic processBH3-interacting domain death agonistHomo sapiens (human)
protein-containing complex assemblyBH3-interacting domain death agonistHomo sapiens (human)
establishment of protein localization to membraneBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaBH3-interacting domain death agonistHomo sapiens (human)
hepatocyte apoptotic processBH3-interacting domain death agonistHomo sapiens (human)
mitochondrial outer membrane permeabilizationBH3-interacting domain death agonistHomo sapiens (human)
supramolecular fiber organizationBH3-interacting domain death agonistHomo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damageBH3-interacting domain death agonistHomo sapiens (human)
regulation of G1/S transition of mitotic cell cycleBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of fibroblast apoptotic processBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of extrinsic apoptotic signaling pathwayBH3-interacting domain death agonistHomo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayBH3-interacting domain death agonistHomo sapiens (human)
apoptotic mitochondrial changesBH3-interacting domain death agonistHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBH3-interacting domain death agonistHomo sapiens (human)
ovarian follicle developmentApoptosis regulator BAX Homo sapiens (human)
neuron migrationApoptosis regulator BAX Homo sapiens (human)
T cell homeostatic proliferationApoptosis regulator BAX Homo sapiens (human)
B cell homeostasisApoptosis regulator BAX Homo sapiens (human)
B cell apoptotic processApoptosis regulator BAX Homo sapiens (human)
kidney developmentApoptosis regulator BAX Homo sapiens (human)
release of cytochrome c from mitochondriaApoptosis regulator BAX Homo sapiens (human)
blood vessel remodelingApoptosis regulator BAX Homo sapiens (human)
myeloid cell homeostasisApoptosis regulator BAX Homo sapiens (human)
B cell negative selectionApoptosis regulator BAX Homo sapiens (human)
B cell homeostatic proliferationApoptosis regulator BAX Homo sapiens (human)
positive regulation of B cell apoptotic processApoptosis regulator BAX Homo sapiens (human)
glycosphingolipid metabolic processApoptosis regulator BAX Homo sapiens (human)
regulation of nitrogen utilizationApoptosis regulator BAX Homo sapiens (human)
apoptotic processApoptosis regulator BAX Homo sapiens (human)
germ cell developmentApoptosis regulator BAX Homo sapiens (human)
mitochondrial fusionApoptosis regulator BAX Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsApoptosis regulator BAX Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageApoptosis regulator BAX Homo sapiens (human)
apoptotic mitochondrial changesApoptosis regulator BAX Homo sapiens (human)
fertilizationApoptosis regulator BAX Homo sapiens (human)
response to toxic substanceApoptosis regulator BAX Homo sapiens (human)
response to salt stressApoptosis regulator BAX Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientApoptosis regulator BAX Homo sapiens (human)
response to gamma radiationApoptosis regulator BAX Homo sapiens (human)
positive regulation of calcium ion transport into cytosolApoptosis regulator BAX Homo sapiens (human)
negative regulation of mitochondrial membrane potentialApoptosis regulator BAX Homo sapiens (human)
hypothalamus developmentApoptosis regulator BAX Homo sapiens (human)
cerebral cortex developmentApoptosis regulator BAX Homo sapiens (human)
positive regulation of protein-containing complex assemblyApoptosis regulator BAX Homo sapiens (human)
negative regulation of protein bindingApoptosis regulator BAX Homo sapiens (human)
endoplasmic reticulum calcium ion homeostasisApoptosis regulator BAX Homo sapiens (human)
negative regulation of endoplasmic reticulum calcium ion concentrationApoptosis regulator BAX Homo sapiens (human)
release of matrix enzymes from mitochondriaApoptosis regulator BAX Homo sapiens (human)
negative regulation of peptidyl-serine phosphorylationApoptosis regulator BAX Homo sapiens (human)
regulation of mammary gland epithelial cell proliferationApoptosis regulator BAX Homo sapiens (human)
cellular response to unfolded proteinApoptosis regulator BAX Homo sapiens (human)
cellular response to UVApoptosis regulator BAX Homo sapiens (human)
ectopic germ cell programmed cell deathApoptosis regulator BAX Homo sapiens (human)
odontogenesis of dentin-containing toothApoptosis regulator BAX Homo sapiens (human)
regulation of apoptotic processApoptosis regulator BAX Homo sapiens (human)
positive regulation of apoptotic processApoptosis regulator BAX Homo sapiens (human)
negative regulation of neuron apoptotic processApoptosis regulator BAX Homo sapiens (human)
positive regulation of neuron apoptotic processApoptosis regulator BAX Homo sapiens (human)
mitochondrial fragmentation involved in apoptotic processApoptosis regulator BAX Homo sapiens (human)
development of secondary sexual characteristicsApoptosis regulator BAX Homo sapiens (human)
retinal cell programmed cell deathApoptosis regulator BAX Homo sapiens (human)
positive regulation of developmental pigmentationApoptosis regulator BAX Homo sapiens (human)
negative regulation of fibroblast proliferationApoptosis regulator BAX Homo sapiens (human)
spermatid differentiationApoptosis regulator BAX Homo sapiens (human)
post-embryonic camera-type eye morphogenesisApoptosis regulator BAX Homo sapiens (human)
response to axon injuryApoptosis regulator BAX Homo sapiens (human)
homeostasis of number of cells within a tissueApoptosis regulator BAX Homo sapiens (human)
protein insertion into mitochondrial membraneApoptosis regulator BAX Homo sapiens (human)
release of sequestered calcium ion into cytosolApoptosis regulator BAX Homo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolApoptosis regulator BAX Homo sapiens (human)
regulation of cell cycleApoptosis regulator BAX Homo sapiens (human)
regulation of mitochondrial membrane potentialApoptosis regulator BAX Homo sapiens (human)
Sertoli cell proliferationApoptosis regulator BAX Homo sapiens (human)
retina development in camera-type eyeApoptosis regulator BAX Homo sapiens (human)
apoptotic process involved in mammary gland involutionApoptosis regulator BAX Homo sapiens (human)
positive regulation of apoptotic process involved in mammary gland involutionApoptosis regulator BAX Homo sapiens (human)
vagina developmentApoptosis regulator BAX Homo sapiens (human)
calcium ion transport into cytosolApoptosis regulator BAX Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressApoptosis regulator BAX Homo sapiens (human)
thymocyte apoptotic processApoptosis regulator BAX Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorApoptosis regulator BAX Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaApoptosis regulator BAX Homo sapiens (human)
motor neuron apoptotic processApoptosis regulator BAX Homo sapiens (human)
apoptotic signaling pathwayApoptosis regulator BAX Homo sapiens (human)
extrinsic apoptotic signaling pathwayApoptosis regulator BAX Homo sapiens (human)
intrinsic apoptotic signaling pathwayApoptosis regulator BAX Homo sapiens (human)
execution phase of apoptosisApoptosis regulator BAX Homo sapiens (human)
supramolecular fiber organizationApoptosis regulator BAX Homo sapiens (human)
cellular response to virusApoptosis regulator BAX Homo sapiens (human)
positive regulation of endoplasmic reticulum unfolded protein responseApoptosis regulator BAX Homo sapiens (human)
positive regulation of mitochondrial membrane permeability involved in apoptotic processApoptosis regulator BAX Homo sapiens (human)
apoptotic process involved in blood vessel morphogenesisApoptosis regulator BAX Homo sapiens (human)
apoptotic process involved in embryonic digit morphogenesisApoptosis regulator BAX Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in programmed necrotic cell deathApoptosis regulator BAX Homo sapiens (human)
positive regulation of apoptotic DNA fragmentationApoptosis regulator BAX Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseApoptosis regulator BAX Homo sapiens (human)
epithelial cell apoptotic processApoptosis regulator BAX Homo sapiens (human)
positive regulation of epithelial cell apoptotic processApoptosis regulator BAX Homo sapiens (human)
B cell receptor apoptotic signaling pathwayApoptosis regulator BAX Homo sapiens (human)
positive regulation of reproductive processApoptosis regulator BAX Homo sapiens (human)
positive regulation of motor neuron apoptotic processApoptosis regulator BAX Homo sapiens (human)
negative regulation of apoptotic signaling pathwayApoptosis regulator BAX Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayApoptosis regulator BAX Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandApoptosis regulator BAX Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process by cytochrome cApoptosis regulator BAX Homo sapiens (human)
response to cytokineBcl-2-like protein 1Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsBcl-2-like protein 1Homo sapiens (human)
ovarian follicle developmentBcl-2-like protein 1Homo sapiens (human)
in utero embryonic developmentBcl-2-like protein 1Homo sapiens (human)
release of cytochrome c from mitochondriaBcl-2-like protein 1Homo sapiens (human)
endocytosisBcl-2-like protein 1Homo sapiens (human)
germ cell developmentBcl-2-like protein 1Homo sapiens (human)
spermatogenesisBcl-2-like protein 1Homo sapiens (human)
male gonad developmentBcl-2-like protein 1Homo sapiens (human)
apoptotic mitochondrial changesBcl-2-like protein 1Homo sapiens (human)
fertilizationBcl-2-like protein 1Homo sapiens (human)
regulation of cytokinesisBcl-2-like protein 1Homo sapiens (human)
positive regulation of mononuclear cell proliferationBcl-2-like protein 1Homo sapiens (human)
ectopic germ cell programmed cell deathBcl-2-like protein 1Homo sapiens (human)
regulation of growthBcl-2-like protein 1Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of neuron apoptotic processBcl-2-like protein 1Homo sapiens (human)
dendritic cell proliferationBcl-2-like protein 1Homo sapiens (human)
response to cycloheximideBcl-2-like protein 1Homo sapiens (human)
regulation of mitochondrial membrane permeabilityBcl-2-like protein 1Homo sapiens (human)
epithelial cell proliferationBcl-2-like protein 1Homo sapiens (human)
negative regulation of developmental processBcl-2-like protein 1Homo sapiens (human)
neuron apoptotic processBcl-2-like protein 1Homo sapiens (human)
defense response to virusBcl-2-like protein 1Homo sapiens (human)
regulation of mitochondrial membrane potentialBcl-2-like protein 1Homo sapiens (human)
cellular response to amino acid stimulusBcl-2-like protein 1Homo sapiens (human)
cellular response to alkaloidBcl-2-like protein 1Homo sapiens (human)
cellular response to gamma radiationBcl-2-like protein 1Homo sapiens (human)
apoptotic process in bone marrow cellBcl-2-like protein 1Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaBcl-2-like protein 1Homo sapiens (human)
dendritic cell apoptotic processBcl-2-like protein 1Homo sapiens (human)
hepatocyte apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of execution phase of apoptosisBcl-2-like protein 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayBcl-2-like protein 1Homo sapiens (human)
negative regulation of protein localization to plasma membraneBcl-2-like protein 1Homo sapiens (human)
negative regulation of reproductive processBcl-2-like protein 1Homo sapiens (human)
negative regulation of dendritic cell apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayBcl-2-like protein 1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 1Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBcl-2-like protein 1Homo sapiens (human)
DNA damage responseInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
response to cytokineInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cell fate determinationInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of autophagyInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cellular homeostasisInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
positive regulation of apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein transmembrane transportInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of anoikisInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial fusionInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
release of cytochrome c from mitochondriaInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
muscle contractionAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
pattern specification processAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
cell population proliferationAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
negative regulation of cell population proliferationAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
regulation of protein stabilityAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
limb morphogenesisAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
positive regulation of proteolysisAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
roof of mouth developmentAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
face morphogenesisAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
activation of cysteine-type endopeptidase activityAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
regulation of protein depolymerizationAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
peptidyl-aspartic acid hydroxylationAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
negative regulation of apoptotic processBcl-2-related protein A1Homo sapiens (human)
transmembrane transportBcl-2-related protein A1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-related protein A1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBcl-2-related protein A1Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl-2-related protein A1Homo sapiens (human)
release of cytochrome c from mitochondriaBcl-2-related protein A1Homo sapiens (human)
mitochondrial fusionBcl-2-related protein A1Homo sapiens (human)
B cell homeostasisBcl-2 homologous antagonist/killerHomo sapiens (human)
B cell apoptotic processBcl-2 homologous antagonist/killerHomo sapiens (human)
release of cytochrome c from mitochondriaBcl-2 homologous antagonist/killerHomo sapiens (human)
blood vessel remodelingBcl-2 homologous antagonist/killerHomo sapiens (human)
myeloid cell homeostasisBcl-2 homologous antagonist/killerHomo sapiens (human)
B cell negative selectionBcl-2 homologous antagonist/killerHomo sapiens (human)
apoptotic processBcl-2 homologous antagonist/killerHomo sapiens (human)
mitochondrial fusionBcl-2 homologous antagonist/killerHomo sapiens (human)
negative regulation of cell population proliferationBcl-2 homologous antagonist/killerHomo sapiens (human)
response to xenobiotic stimulusBcl-2 homologous antagonist/killerHomo sapiens (human)
response to fungusBcl-2 homologous antagonist/killerHomo sapiens (human)
response to mycotoxinBcl-2 homologous antagonist/killerHomo sapiens (human)
response to UV-CBcl-2 homologous antagonist/killerHomo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientBcl-2 homologous antagonist/killerHomo sapiens (human)
response to gamma radiationBcl-2 homologous antagonist/killerHomo sapiens (human)
positive regulation of calcium ion transport into cytosolBcl-2 homologous antagonist/killerHomo sapiens (human)
negative regulation of gene expressionBcl-2 homologous antagonist/killerHomo sapiens (human)
response to organic cyclic compoundBcl-2 homologous antagonist/killerHomo sapiens (human)
endocrine pancreas developmentBcl-2 homologous antagonist/killerHomo sapiens (human)
animal organ regenerationBcl-2 homologous antagonist/killerHomo sapiens (human)
positive regulation of protein-containing complex assemblyBcl-2 homologous antagonist/killerHomo sapiens (human)
endoplasmic reticulum calcium ion homeostasisBcl-2 homologous antagonist/killerHomo sapiens (human)
negative regulation of endoplasmic reticulum calcium ion concentrationBcl-2 homologous antagonist/killerHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationBcl-2 homologous antagonist/killerHomo sapiens (human)
cellular response to unfolded proteinBcl-2 homologous antagonist/killerHomo sapiens (human)
cellular response to UVBcl-2 homologous antagonist/killerHomo sapiens (human)
limb morphogenesisBcl-2 homologous antagonist/killerHomo sapiens (human)
response to hydrogen peroxideBcl-2 homologous antagonist/killerHomo sapiens (human)
positive regulation of apoptotic processBcl-2 homologous antagonist/killerHomo sapiens (human)
fibroblast apoptotic processBcl-2 homologous antagonist/killerHomo sapiens (human)
response to ethanolBcl-2 homologous antagonist/killerHomo sapiens (human)
positive regulation of proteolysisBcl-2 homologous antagonist/killerHomo sapiens (human)
regulation of mitochondrial membrane permeabilityBcl-2 homologous antagonist/killerHomo sapiens (human)
post-embryonic camera-type eye morphogenesisBcl-2 homologous antagonist/killerHomo sapiens (human)
epithelial cell proliferationBcl-2 homologous antagonist/killerHomo sapiens (human)
establishment of localization in cellBcl-2 homologous antagonist/killerHomo sapiens (human)
regulation of cell cycleBcl-2 homologous antagonist/killerHomo sapiens (human)
regulation of mitochondrial membrane potentialBcl-2 homologous antagonist/killerHomo sapiens (human)
vagina developmentBcl-2 homologous antagonist/killerHomo sapiens (human)
calcium ion transport into cytosolBcl-2 homologous antagonist/killerHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressBcl-2 homologous antagonist/killerHomo sapiens (human)
thymocyte apoptotic processBcl-2 homologous antagonist/killerHomo sapiens (human)
cellular response to mechanical stimulusBcl-2 homologous antagonist/killerHomo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaBcl-2 homologous antagonist/killerHomo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaBcl-2 homologous antagonist/killerHomo sapiens (human)
apoptotic signaling pathwayBcl-2 homologous antagonist/killerHomo sapiens (human)
intrinsic apoptotic signaling pathwayBcl-2 homologous antagonist/killerHomo sapiens (human)
activation of cysteine-type endopeptidase activityBcl-2 homologous antagonist/killerHomo sapiens (human)
positive regulation of endoplasmic reticulum unfolded protein responseBcl-2 homologous antagonist/killerHomo sapiens (human)
negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayBcl-2 homologous antagonist/killerHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayBcl-2 homologous antagonist/killerHomo sapiens (human)
apoptotic process involved in blood vessel morphogenesisBcl-2 homologous antagonist/killerHomo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseBcl-2 homologous antagonist/killerHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBcl-2 homologous antagonist/killerHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl-2 homologous antagonist/killerHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl-2 homologous antagonist/killerHomo sapiens (human)
response to ischemiaBcl-2-like protein 2Homo sapiens (human)
spermatogenesisBcl-2-like protein 2Homo sapiens (human)
negative regulation of mitochondrial membrane permeabilityBcl-2-like protein 2Homo sapiens (human)
regulation of apoptotic processBcl-2-like protein 2Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 2Homo sapiens (human)
Sertoli cell proliferationBcl-2-like protein 2Homo sapiens (human)
cellular response to estradiol stimulusBcl-2-like protein 2Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaBcl-2-like protein 2Homo sapiens (human)
cellular response to amyloid-betaBcl-2-like protein 2Homo sapiens (human)
cellular response to glycineBcl-2-like protein 2Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 2Homo sapiens (human)
release of cytochrome c from mitochondriaBcl-2-like protein 2Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 2Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBcl-2-like protein 2Homo sapiens (human)
glucose catabolic processBcl2-associated agonist of cell death Homo sapiens (human)
apoptotic processBcl2-associated agonist of cell death Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBcl2-associated agonist of cell death Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptorsBcl2-associated agonist of cell death Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of autophagyBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of mitochondrial membrane potentialBcl2-associated agonist of cell death Homo sapiens (human)
cytokine-mediated signaling pathwayBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of insulin secretionBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of glucokinase activityBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusBcl2-associated agonist of cell death Homo sapiens (human)
glucose homeostasisBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of apoptotic processBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processBcl2-associated agonist of cell death Homo sapiens (human)
type B pancreatic cell proliferationBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of B cell differentiationBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of T cell differentiationBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of proteolysisBcl2-associated agonist of cell death Homo sapiens (human)
ADP metabolic processBcl2-associated agonist of cell death Homo sapiens (human)
ATP metabolic processBcl2-associated agonist of cell death Homo sapiens (human)
regulation of mitochondrial membrane permeabilityBcl2-associated agonist of cell death Homo sapiens (human)
pore complex assemblyBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of epithelial cell proliferationBcl2-associated agonist of cell death Homo sapiens (human)
cellular response to mechanical stimulusBcl2-associated agonist of cell death Homo sapiens (human)
cellular response to nicotineBcl2-associated agonist of cell death Homo sapiens (human)
cellular response to lipidBcl2-associated agonist of cell death Homo sapiens (human)
cellular response to hypoxiaBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaBcl2-associated agonist of cell death Homo sapiens (human)
extrinsic apoptotic signaling pathwayBcl2-associated agonist of cell death Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl2-associated agonist of cell death Homo sapiens (human)
intrinsic apoptotic signaling pathwayBcl2-associated agonist of cell death Homo sapiens (human)
activation of cysteine-type endopeptidase activityBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway in response to osmotic stressBcl2-associated agonist of cell death Homo sapiens (human)
positive regulation of type B pancreatic cell developmentBcl2-associated agonist of cell death Homo sapiens (human)
release of cytochrome c from mitochondriaBcl2-associated agonist of cell death Homo sapiens (human)
apoptotic processBcl-2-like protein 10Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBcl-2-like protein 10Homo sapiens (human)
spermatogenesisBcl-2-like protein 10Homo sapiens (human)
female gamete generationBcl-2-like protein 10Homo sapiens (human)
microtubule organizing center organizationBcl-2-like protein 10Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 10Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 10Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 10Homo sapiens (human)
release of cytochrome c from mitochondriaBcl-2-like protein 10Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (45)

Processvia Protein(s)Taxonomy
protein bindingBcl-2-like protein 11Homo sapiens (human)
microtubule bindingBcl-2-like protein 11Homo sapiens (human)
protein kinase bindingBcl-2-like protein 11Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
cysteine-type endopeptidase inhibitor activityBeta-caseinBos taurus (cattle)
protein bindingBeta-caseinBos taurus (cattle)
antioxidant activityBeta-caseinBos taurus (cattle)
potassium channel inhibitor activityBeta-caseinBos taurus (cattle)
protein homodimerization activityBeta-caseinBos taurus (cattle)
metal ion bindingBeta-caseinBos taurus (cattle)
protease bindingApoptosis regulator Bcl-2Homo sapiens (human)
protein bindingApoptosis regulator Bcl-2Homo sapiens (human)
channel activityApoptosis regulator Bcl-2Homo sapiens (human)
channel inhibitor activityApoptosis regulator Bcl-2Homo sapiens (human)
ubiquitin protein ligase bindingApoptosis regulator Bcl-2Homo sapiens (human)
identical protein bindingApoptosis regulator Bcl-2Homo sapiens (human)
sequence-specific DNA bindingApoptosis regulator Bcl-2Homo sapiens (human)
protein heterodimerization activityApoptosis regulator Bcl-2Homo sapiens (human)
BH3 domain bindingApoptosis regulator Bcl-2Homo sapiens (human)
protein phosphatase 2A bindingApoptosis regulator Bcl-2Homo sapiens (human)
molecular adaptor activityApoptosis regulator Bcl-2Homo sapiens (human)
DNA-binding transcription factor bindingApoptosis regulator Bcl-2Homo sapiens (human)
BH domain bindingApoptosis regulator Bcl-2Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
death receptor bindingBH3-interacting domain death agonistHomo sapiens (human)
protein bindingBH3-interacting domain death agonistHomo sapiens (human)
ubiquitin protein ligase bindingBH3-interacting domain death agonistHomo sapiens (human)
protein bindingApoptosis regulator BAX Homo sapiens (human)
lipid bindingApoptosis regulator BAX Homo sapiens (human)
channel activityApoptosis regulator BAX Homo sapiens (human)
Hsp70 protein bindingApoptosis regulator BAX Homo sapiens (human)
identical protein bindingApoptosis regulator BAX Homo sapiens (human)
protein homodimerization activityApoptosis regulator BAX Homo sapiens (human)
protein heterodimerization activityApoptosis regulator BAX Homo sapiens (human)
BH3 domain bindingApoptosis regulator BAX Homo sapiens (human)
BH domain bindingApoptosis regulator BAX Homo sapiens (human)
protein bindingBcl-2-like protein 1Homo sapiens (human)
protein kinase bindingBcl-2-like protein 1Homo sapiens (human)
identical protein bindingBcl-2-like protein 1Homo sapiens (human)
BH3 domain bindingBcl-2-like protein 1Homo sapiens (human)
BH domain bindingBcl-2-like protein 1Homo sapiens (human)
protein bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein transmembrane transporter activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein heterodimerization activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
BH3 domain bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
channel activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
BH domain bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
structural molecule activityAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
calcium ion bindingAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
protein bindingAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
structural constituent of muscleAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
electron transfer activityAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
peptidyl-aspartic acid 3-dioxygenase activityAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
protein bindingBcl-2-related protein A1Homo sapiens (human)
channel activityBcl-2-related protein A1Homo sapiens (human)
BH domain bindingBcl-2-related protein A1Homo sapiens (human)
molecular_functionBcl-2 homologous antagonist/killerHomo sapiens (human)
protein bindingBcl-2 homologous antagonist/killerHomo sapiens (human)
porin activityBcl-2 homologous antagonist/killerHomo sapiens (human)
heat shock protein bindingBcl-2 homologous antagonist/killerHomo sapiens (human)
identical protein bindingBcl-2 homologous antagonist/killerHomo sapiens (human)
protein homodimerization activityBcl-2 homologous antagonist/killerHomo sapiens (human)
transmembrane transporter bindingBcl-2 homologous antagonist/killerHomo sapiens (human)
protein-containing complex bindingBcl-2 homologous antagonist/killerHomo sapiens (human)
metal ion bindingBcl-2 homologous antagonist/killerHomo sapiens (human)
protein heterodimerization activityBcl-2 homologous antagonist/killerHomo sapiens (human)
protein-folding chaperone bindingBcl-2 homologous antagonist/killerHomo sapiens (human)
BH domain bindingBcl-2 homologous antagonist/killerHomo sapiens (human)
protein bindingBcl-2-like protein 2Homo sapiens (human)
identical protein bindingBcl-2-like protein 2Homo sapiens (human)
protein-containing complex bindingBcl-2-like protein 2Homo sapiens (human)
disordered domain specific bindingBcl-2-like protein 2Homo sapiens (human)
BH domain bindingBcl-2-like protein 2Homo sapiens (human)
protein bindingBcl2-associated agonist of cell death Homo sapiens (human)
phospholipid bindingBcl2-associated agonist of cell death Homo sapiens (human)
lipid bindingBcl2-associated agonist of cell death Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processBcl2-associated agonist of cell death Homo sapiens (human)
protein kinase bindingBcl2-associated agonist of cell death Homo sapiens (human)
protein phosphatase bindingBcl2-associated agonist of cell death Homo sapiens (human)
calcium ion bindingBcl-2-like protein 10Homo sapiens (human)
protein bindingBcl-2-like protein 10Homo sapiens (human)
caspase bindingBcl-2-like protein 10Homo sapiens (human)
BH domain bindingBcl-2-like protein 10Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (36)

Processvia Protein(s)Taxonomy
mitochondrial outer membraneBcl-2-like protein 11Homo sapiens (human)
cytosolBcl-2-like protein 11Homo sapiens (human)
endomembrane systemBcl-2-like protein 11Homo sapiens (human)
Bcl-2 family protein complexBcl-2-like protein 11Homo sapiens (human)
mitochondrionBcl-2-like protein 11Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
extracellular spaceBeta-caseinBos taurus (cattle)
Golgi apparatusBeta-caseinBos taurus (cattle)
Golgi lumenBeta-caseinBos taurus (cattle)
mitochondrial outer membraneApoptosis regulator Bcl-2Homo sapiens (human)
endoplasmic reticulum membraneApoptosis regulator Bcl-2Homo sapiens (human)
nucleusApoptosis regulator Bcl-2Homo sapiens (human)
cytoplasmApoptosis regulator Bcl-2Homo sapiens (human)
mitochondrionApoptosis regulator Bcl-2Homo sapiens (human)
mitochondrial outer membraneApoptosis regulator Bcl-2Homo sapiens (human)
endoplasmic reticulumApoptosis regulator Bcl-2Homo sapiens (human)
cytosolApoptosis regulator Bcl-2Homo sapiens (human)
membraneApoptosis regulator Bcl-2Homo sapiens (human)
nuclear membraneApoptosis regulator Bcl-2Homo sapiens (human)
myelin sheathApoptosis regulator Bcl-2Homo sapiens (human)
BAD-BCL-2 complexApoptosis regulator Bcl-2Homo sapiens (human)
protein-containing complexApoptosis regulator Bcl-2Homo sapiens (human)
pore complexApoptosis regulator Bcl-2Homo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
mitochondrial outer membraneBH3-interacting domain death agonistHomo sapiens (human)
cytosolBH3-interacting domain death agonistHomo sapiens (human)
membraneBH3-interacting domain death agonistHomo sapiens (human)
mitochondrionBH3-interacting domain death agonistHomo sapiens (human)
cytosolBH3-interacting domain death agonistHomo sapiens (human)
cell peripheryApoptosis regulator BAX Homo sapiens (human)
nucleusApoptosis regulator BAX Homo sapiens (human)
nuclear envelopeApoptosis regulator BAX Homo sapiens (human)
cytoplasmApoptosis regulator BAX Homo sapiens (human)
mitochondrionApoptosis regulator BAX Homo sapiens (human)
mitochondrial outer membraneApoptosis regulator BAX Homo sapiens (human)
endoplasmic reticulumApoptosis regulator BAX Homo sapiens (human)
endoplasmic reticulum membraneApoptosis regulator BAX Homo sapiens (human)
cytosolApoptosis regulator BAX Homo sapiens (human)
membraneApoptosis regulator BAX Homo sapiens (human)
extracellular exosomeApoptosis regulator BAX Homo sapiens (human)
mitochondrial permeability transition pore complexApoptosis regulator BAX Homo sapiens (human)
pore complexApoptosis regulator BAX Homo sapiens (human)
Bcl-2 family protein complexApoptosis regulator BAX Homo sapiens (human)
BAX complexApoptosis regulator BAX Homo sapiens (human)
BAK complexApoptosis regulator BAX Homo sapiens (human)
mitochondrial outer membraneApoptosis regulator BAX Homo sapiens (human)
cytoplasmBcl-2-like protein 1Homo sapiens (human)
mitochondrionBcl-2-like protein 1Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 1Homo sapiens (human)
mitochondrial inner membraneBcl-2-like protein 1Homo sapiens (human)
mitochondrial matrixBcl-2-like protein 1Homo sapiens (human)
endoplasmic reticulumBcl-2-like protein 1Homo sapiens (human)
centrosomeBcl-2-like protein 1Homo sapiens (human)
cytosolBcl-2-like protein 1Homo sapiens (human)
synaptic vesicle membraneBcl-2-like protein 1Homo sapiens (human)
nuclear membraneBcl-2-like protein 1Homo sapiens (human)
Bcl-2 family protein complexBcl-2-like protein 1Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 1Homo sapiens (human)
nucleusInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
nucleoplasmInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cytoplasmInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrionInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial outer membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cytosolInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
Bcl-2 family protein complexInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial outer membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
endoplasmic reticulumAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
endoplasmic reticulum membraneAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
plasma membraneAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
cortical endoplasmic reticulumAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
sarcoplasmic reticulum membraneAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
endoplasmic reticulumAspartyl/asparaginyl beta-hydroxylaseHomo sapiens (human)
cytoplasmBcl-2-related protein A1Homo sapiens (human)
cytosolBcl-2-related protein A1Homo sapiens (human)
mitochondrial outer membraneBcl-2-related protein A1Homo sapiens (human)
mitochondrial outer membraneBcl-2 homologous antagonist/killerHomo sapiens (human)
mitochondrionBcl-2 homologous antagonist/killerHomo sapiens (human)
mitochondrial outer membraneBcl-2 homologous antagonist/killerHomo sapiens (human)
endoplasmic reticulumBcl-2 homologous antagonist/killerHomo sapiens (human)
cytosolBcl-2 homologous antagonist/killerHomo sapiens (human)
Bcl-2 family protein complexBcl-2 homologous antagonist/killerHomo sapiens (human)
BAK complexBcl-2 homologous antagonist/killerHomo sapiens (human)
pore complexBcl-2 homologous antagonist/killerHomo sapiens (human)
cytosolBcl-2-like protein 2Homo sapiens (human)
Bcl-2 family protein complexBcl-2-like protein 2Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 2Homo sapiens (human)
mitochondrionBcl2-associated agonist of cell death Homo sapiens (human)
mitochondrial outer membraneBcl2-associated agonist of cell death Homo sapiens (human)
cytosolBcl2-associated agonist of cell death Homo sapiens (human)
BAD-BCL-2 complexBcl2-associated agonist of cell death Homo sapiens (human)
cytosolBcl2-associated agonist of cell death Homo sapiens (human)
mitochondrionBcl2-associated agonist of cell death Homo sapiens (human)
mitochondrial outer membraneBcl-2-binding component 3, isoforms 1/2Homo sapiens (human)
cytosolBcl-2-binding component 3, isoforms 1/2Homo sapiens (human)
mitochondrionBcl-2-like protein 10Homo sapiens (human)
endoplasmic reticulumBcl-2-like protein 10Homo sapiens (human)
spindleBcl-2-like protein 10Homo sapiens (human)
cytosolBcl-2-like protein 10Homo sapiens (human)
membraneBcl-2-like protein 10Homo sapiens (human)
nuclear membraneBcl-2-like protein 10Homo sapiens (human)
mitochondria-associated endoplasmic reticulum membrane contact siteBcl-2-like protein 10Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 10Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (357)

Assay IDTitleYearJournalArticle
AID1178317Binding affinity to induced myeloid leukemia cell differentiation protein 1 (unknown origin)2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Biased and unbiased strategies to identify biologically active small molecules.
AID1320544Inhibition of 5-FAM-Bid peptide binding to Bcl-2 (unknown origin) by fluorescence polarization assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID1816664Cytotoxicity against MCL-1deficient MEF cells assessed as release of cytochrome c from mitochondria at 2.5 uM FACS analysis
AID701530Induction of apoptosis in human RS4:11 cells at 10 uM incubated for 24 hrs by Annexin V and propidium iodide staining based FACS method2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID1690752Antiproliferative activity against human MOLT-4 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
AID721471Binding affinity to Bcl-2 (unknown origin) fluorescence polarization assay2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1.
AID1690776Induction of apoptosis in human MOLT-4 cells assessed as viable cells at 100 nM measured after 48 hrs by Alexa Fluor 647-Annexin V/propidium iodide staining based flow cytometry (Rvb = 97.1 to 97.3%)
AID330751Induction of apoptosis in mouse Eu-Myc cells overexpressing BCL2 assessed as inhibition of colony formation at 1 uM2007Proceedings of the National Academy of Sciences of the United States of America, Dec-04, Volume: 104, Issue:49
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
AID277492Inhibition of cell growth in human RS11380 cells overexpressing Bcl2 in presence of 10% HS2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID654462Binding affinity to Bcl-xL2012European journal of medicinal chemistry, May, Volume: 51Structure-activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction.
AID1296620Cell cycle arrest in human HCT116 p53-/- cells assessed as accumulation at G1 phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 28%)2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1816652Inhibition of GST tagged human/mouse chimeric MCL-1 using biotin-DLRPEIRIAQELRIZIGDEFNETYTRR as substrate incubated for 40 mins followed by substrate addition measured after 4 hrs by AlphaSCREEN assay
AID628484Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 V141A mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID1580122Inhibition of Bcl-xL (unknown origin) by surface plasmon resonance assay2020Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3
Hot-Spots of Mcl-1 Protein.
AID421428Cytotoxicity against human BP3 cells expressing Bfl1/Mcl1 by FITC-annexin V and propidium iodide assay2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Apogossypol derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
AID389262Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl2 assessed as cell viability after 24 hrs by MTS assay in absence of serum2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
AID1352851Cytotoxicity against human K562 cells assessed as reduction in cell viability at 1 to 2 uM by CellTiter-Glo luminescent assay relative to control2018European journal of medicinal chemistry, Feb-25, Volume: 146Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
AID628398Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 F97V mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID277485Displacement of Bad-derived peptide from Bcl-xL by fluorescence polarization assay2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID462447Inhibition of Bcl-xL2010Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
Fragment-based deconstruction of Bcl-xL inhibitors.
AID640028Binding affinity to Bcl-2 by competitive fluorescence polarization assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
AID1483465Binding affinity to Mcl-1 (unknown origin)2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.
AID587011Displacement of wild type mBimBH3 from human Bcl-w by solution competition assay2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
AID640029Binding affinity to Mcl-1 by competitive fluorescence polarization assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
AID1178315Binding affinity to Bcl-w (unknown origin)2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Biased and unbiased strategies to identify biologically active small molecules.
AID701519Inhibition of GST-tagged recombinant Bcl-XL interaction with biotinylated Bim peptide by ELISA based competitive binding assay2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID587087Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% fetal bovine serum2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
AID654460Inhibition of Rluc-Bax/eYFP-Bcl-xL interaction expressed in human HeLa cells at 10 uM after 16 hrs by BRET assay2012European journal of medicinal chemistry, May, Volume: 51Structure-activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction.
AID1635029Inhibition of His-tagged Mcl-1/5-carboxyfluorescein-Bid (unknown origin) after 1 hr by fluorescence polarization assay2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Anacardic Acids from Knema hookeriana as Modulators of Bcl-xL/Bak and Mcl-1/Bid Interactions.
AID1851858Selectivity ratio, Ki for inhibition of MCL-1 (unknown origin) to Ki for inhibition of BCL-2 (unknown origin)2022RSC medicinal chemistry, Aug-17, Volume: 13, Issue:8
Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads.
AID1545357Inhibition of BCL-W (unknown origin) in presence of 10% human serum incubated for 15 mins by fluorescence polarization assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Clinical candidates modulating protein-protein interactions: The fragment-based experience.
AID1224377Displacement of fluorescein-labeled BAK from His-tagged BCL-XL (unknown origin) after 1 hr by fluorescence polarization assay2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Endiandric acid analogues from Beilschmiedia ferruginea as dual inhibitors of Bcl-xL/Bak and Mcl-1/Bid interactions.
AID281476Induction of cell death in human MDA-MB-231 cells after 96 hrs by trypan blue exclusion assay2007Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8
Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.
AID687164Ratio of IC50 for doxorubicin-resistant human K562 cells to IC50 for human K562 cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID701528Binding affinity to Bcl-XL2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID727588Induction of apoptosis in human Toledo cells2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
The role of the acidity of N-heteroaryl sulfonamides as inhibitors of bcl-2 family protein-protein interactions.
AID1893751Selectivity ratio of IC50 for inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS to IC50 for inhibition of biotin-linker-Beclin 1 BH3 peptide bi2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
Novel Bcl-2 Inhibitors Selectively Disrupt the Autophagy-Specific Bcl-2-Beclin 1 Protein-Protein Interaction.
AID1851857Inhibition of BCL-xL (unknown origin) by fluorescence polarization competition assay2022RSC medicinal chemistry, Aug-17, Volume: 13, Issue:8
Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads.
AID330776Binding affinity to BCL22007Proceedings of the National Academy of Sciences of the United States of America, Dec-04, Volume: 104, Issue:49
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
AID687160Ratio of IC50 for human HL60/MX2 cells to IC50 for human HL60 cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID330756Cytotoxicity in human siRNA-mediated-MCL1-kncok down KB cells overexpressing BCL2 at 0.5 uM2007Proceedings of the National Academy of Sciences of the United States of America, Dec-04, Volume: 104, Issue:49
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
AID628399Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 R100E mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID675723Growth inhibition of human NCI-H146 cells after 4 days by WST8 assay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold.
AID330758Cytotoxicity in human KB cells overexpressing BCL2 at 0.1 uM2007Proceedings of the National Academy of Sciences of the United States of America, Dec-04, Volume: 104, Issue:49
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
AID389265Cmax in Sprague-Dawley rat at 5 mg/kg, po2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
AID1296624Cell cycle arrest in human HCT116 p53+/+ cells assessed as accumulation at G1 phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 31%)2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1881901Inhibition of PKM2 (unknown origin) Leu180, Asp177, Lys207, Hie78, Thr328, GIn329, Gly363, Lys367 residues2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID694161Antagonist activity at recombinant Bcl-XL assessed as restoration of BIM BH3-induced cytochrome c release in mitochondria isolated from MDA-MB-231 cells at 0.03 to 1 uM after 1 hr by Western blot analysis2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID652718Induction of Bcl-xL-mediated apoptosis in doxycyclin-stimulated human HeLa cells expressing GFP at 1 uM after 12 hrs by Hoechst staining2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.
AID1690759Antiproliferative activity against human NCI-H146 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
AID1690761Selectivity index, ratio of IC50 for human platelet to IC50 for human MOLT-4 cells
AID431392Cytotoxicity against human SU-8686 cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID1296627Induction of apoptosis in human HCT116 p53+/+ cells after 48 hrs by Annexin V-FITC staining-based flow cytometric method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID687157Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1690780Induction of apoptosis in human MOLT-4 cells assessed as viable cells at 100 nM measured after 48 hrs in presence of pan-caspase inhibitor QVD by Alexa Fluor 647-Annexin V/propidium iodide staining based flow cytometry (Rvb = 97.1 to 97.3%)
AID389266AUC in Sprague-Dawley rat at 5 mg/kg, po2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
AID1194221Inhibition of GST-tagged Bcl-xL (unknown origin) measured after 1 hr incubation by fluorescence polarization assay2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
A combination of in silico and SAR studies to identify binding hot spots of Bcl-xL inhibitors.
AID1353864Cytotoxicity against human BL2 cells assessed as reduction in cell viability after 24 hrs by MTT assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.
AID1296626Cell cycle arrest in human HCT116 p53-/- cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 35%)2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1320551Growth inhibition of human MCF7 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID277489Inhibition of cell growth in human DoHH2 cells overexpressing Bcl2 in presence of 3% FBS2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID1483464Inhibition of Bcl-w (unknown origin)2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.
AID1296636Induction of apoptosis in human DMS53 cells harboring p53 mutant assessed as caspase-3 cleavage at 5 to 10 uM after 12 hrs by immunoblotting method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID389268Ratio of AUC for Sprague-Dawley rat at 5 mg/kg, po to EC50 for human NCI-H146 cells in presence of 10% human serum2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
AID1293715Inhibition of human Bcl-2 deltaC22 mutant by surface plasmon resonance method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity.
AID1635028Inhibition of His-tagged Bcl-xL/5-carboxyfluorescein-Bak (unknown origin) after 1 hr by fluorescence polarization assay2016Journal of natural products, Apr-22, Volume: 79, Issue:4
Anacardic Acids from Knema hookeriana as Modulators of Bcl-xL/Bak and Mcl-1/Bid Interactions.
AID1816660Cytotoxicity against MCL-1/BAX/BAK deficient mouse embryonic fibroblast cells assessed as reduction in cell viability in presence of 1 % fetal calf serum measured after 24 hrs propidium iodide staining based flow cytometric analysis
AID694155Antiproliferative activity against human NCI-H1417 cells after 4 days by WST8 assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID1320546Inhibition of 5-FAM-Bid peptide binding to MCL-1 (unknown origin) by fluorescence polarization assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID277494Inhibition of cell growth in human SUDHL4 cells overexpressing Bcl2 in presence of 10% HS2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID675721Binding affinity to N-terminus 8X His-tagged human Bcl-xL expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold.
AID1545370Half life in mouse2019European journal of medicinal chemistry, Apr-01, Volume: 167Clinical candidates modulating protein-protein interactions: The fragment-based experience.
AID694168Antagonist activity at recombinant Mcl1 assessed as restoration of BIM BH3-induced Smac protein release in mitochondria isolated from MDA-MB-231 cells at 10 uM after 1 hr by Western blot analysis2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID727589Solubility of compound in fasted state simulated intestinal fluid2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
The role of the acidity of N-heteroaryl sulfonamides as inhibitors of bcl-2 family protein-protein interactions.
AID526646Binding affinity to BCl22010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
AID431390Cytotoxicity against human H460 cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID1296632Inhibition of BCl-2/Bim interaction in human DMS53 cells harboring p53 mutant at 5 to 10 uM after 12 hrs by immunoprecipitation method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID389261Displacement of fluorescein labeled Bax peptide from Bcl2 by fluorescence polarization assay2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
AID1677971Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) at 20uM using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID694152Inhibition of human N-terminal His8-tagged Bcl-XL expressed in Escherichia coli BL21(DE3) assessed as inhibition of Fluorescein-labeled BAK binding after 1 to 2 hrs by fluorescence polarization assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID431384Cytotoxicity against human Jurkat cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID1296638Induction of apoptosis in human DMS53 cells harboring p53 mutant assessed as PARP cleavage at 5 to 10 uM after 12 hrs by immunoblotting method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID431388Cytotoxicity against human HCT116 cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID587008Displacement of biotinylated Bim-BH3 from GST-tagged Bcl-Xl by AlphaScreen competitive assay2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
AID1816654Inhibition of human BCL-2 deltaC22 by surface plasmon resonance assay
AID694167Antagonist activity at recombinant Mcl1 assessed as restoration of BIM BH3-induced cytochrome c release in mitochondria isolated from MDA-MB-231 cells at 10 uM after 1 hr by Western blot analysis2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID330752Induction of apoptosis in mouse Eu-Myc cells overexpressing A1 assessed as inhibition of colony formation at 1 uM2007Proceedings of the National Academy of Sciences of the United States of America, Dec-04, Volume: 104, Issue:49
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
AID628349Binding affinity for GST-tagged mouse MCL1 expressed in Escherichia coli BL21 cells2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID710843Binding affinity to Bcl-22012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
An anthraquinone scaffold for putative, two-face Bim BH3 α-helix mimic.
AID756761Binding affinity to human/mouse chimeric Mcl-1 by luminescence proximity assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
AID756759Binding affinity to human GST-tagged Bcl-Xl by luminescence proximity assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
AID1545367Oral bioavailability in monkey2019European journal of medicinal chemistry, Apr-01, Volume: 167Clinical candidates modulating protein-protein interactions: The fragment-based experience.
AID1677972Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID1353865Cytotoxicity against human Remb1 cells assessed as reduction in cell viability after 24 hrs by MTT assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.
AID701526Binding affinity to Bcl-w2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID587090Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 1% serum2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
AID694153Inhibition of human N-terminal His8-tagged Mcl1 expressed in Escherichia coli BL21(DE3) assessed as inhibition of Fluorescein-labeled BID binding after 1 to 2 hrs by fluorescence polarization assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID628487Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 Y195F mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID701518Inhibition of GST-tagged recombinant Bcl2 interaction with biotinylated Bim peptide by ELISA based competitive binding assay2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID587089Cytotoxicity against mouse MEF cells expressing mcl-1 fl/fl after 24 hrs by Cell titer glo assay in presence of 1% serum2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
AID330762Cytotoxicity against BCL2 overexpressing human KB cells transfected with MCL1 siRNA assessed as propidium iodide uptake at 0.5 uM after 72 hrs by flow cytometry2007Proceedings of the National Academy of Sciences of the United States of America, Dec-04, Volume: 104, Issue:49
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
AID526652Aqueous solubility of the compound2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
AID701531Induction of apoptosis in human IM9 cells at 10 uM incubated for 24 hrs by Annexin V and propidium iodide staining based FACS method2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID727591Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
The role of the acidity of N-heteroaryl sulfonamides as inhibitors of bcl-2 family protein-protein interactions.
AID515598Inhibition of GST-tagged Bel-xl/FITC-conjugated Bak interaction by fluorescence polarisation assay2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
Synthesis and biological activities of new di- and trimeric quinoline derivatives.
AID628489Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A142Gdelta136T mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID728130Cytotoxicity against human NCI-H187 cells assessed as growth inhibition after 4 days by WST assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
A potent and highly efficacious Bcl-2/Bcl-xL inhibitor.
AID694151Inhibition of human N-terminal His6-tagged Bcl2 isoform 2 expressed in Escherichia coli BL21(DE3) assessed as inhibition of Fluorescein-labeled BIM binding after 1 to 2 hrs by fluorescence polarization assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID587096Displacement of wild type mBimBH3 from Mcl-1 by solution competition assay2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
AID721795Induction of apoptosis in Mcl1 dependent human K562 cells after 48 hrs by Annexin V staining based flow cytometry2013European journal of medicinal chemistry, Feb, Volume: 60Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.
AID1545371Oral bioavailability in mouse2019European journal of medicinal chemistry, Apr-01, Volume: 167Clinical candidates modulating protein-protein interactions: The fragment-based experience.
AID701517Inhibition of GST-tagged recombinant Mcl1 interaction with biotinylated Bim peptide by ELISA based competitive binding assay2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID640093Cytotoxicity against human MDA-MB-435 cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
AID701521Induction of cell death in mouse MEF cells containing Bax/Bak double knock out at 10 uM by Annexin V and propidium iodide staining based FACS method2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID1388439Inhibition of Bcl-xL (unknown origin)2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.
AID694171Induction of apoptosis in human NCI-H146 cells assessed as caspase3 activation after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID1296633Inhibition of BCl-2/Bax interaction in human DMS53 cells harboring p53 mutant at 5 to 10 uM after 12 hrs by immunoprecipitation method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID756749Cytotoxicity against mcl-1 deficient MFF assessed as cell viability after overnight incubation by celltiter-blue assay in presence of 10% FBS2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
AID1816659Cytotoxicity against wild type mouse embryonic fibroblast cells assessed as reduction in cell viability in presence of 1 % fetal calf serum measured after 24 hrs propidium iodide staining based flow cytometric analysis
AID628402Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 L130A mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID628404Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 L130V mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID1483463Inhibition of Bcl-xL (unknown origin)2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.
AID1690782Induction of apoptosis in human MOLT-4 cells assessed as late apoptotic cells at 100 nM measured after 48 hrs in presence of pan-caspase inhibitor QVD by Alexa Fluor 647-Annexin V/propidium iodide staining based flow cytometry (Rvb = 1.1 to 1.4%)
AID640030Cytotoxicity against human Raji cells expressing Bcl-xL, Bcl-2 and Mcl-1 at 100 ug/ml after 72 hrs by MTT assay relative to control2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
AID675720Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold.
AID721796Induction of apoptosis in Bcl2 dependent human RS4:11 cells after 48 hrs by Annexin V staining based flow cytometry2013European journal of medicinal chemistry, Feb, Volume: 60Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors.
AID1545366Half life in monkey2019European journal of medicinal chemistry, Apr-01, Volume: 167Clinical candidates modulating protein-protein interactions: The fragment-based experience.
AID687162Ratio of IC50 for daunorubicin-resistant human HL60 cells to IC50 for human HL60 cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1677973Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with high 200 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID1296623Cell cycle arrest in human HCT116 p53+/+ cells assessed as accumulation at S phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 42%)2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1690758Antiproliferative activity against human RS4-11 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
AID1388440Antiproliferative activity against human RS4:11 cells in presence of 10% human serum2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.
AID1677974Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using 1 uM hFX-CP as substrate mixture with 3 uM 2OG, 100 uM L-ascorbic acid and high 20 uM FAS incubated for 35 mins by MS analysis2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID318565Binding affinity to Bcl-XL assessed as inhibition of Bcl-XL-BAD derived peptide interaction2007Nature, Dec-13, Volume: 450, Issue:7172
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.
AID431387Cytotoxicity against human DU145 cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID687167Ratio of IC50 for human CCRF-CEM/VM-1-5 cells IC50 for human CCRF-CEM cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1296625Cell cycle arrest in human HCT116 p53-/- cells assessed as accumulation at S phase at 10 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 36%)2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID671072Inhibition of Bcl-XL2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein.
AID683534Inhibition of Mcl1-BAK interaction2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
Lipophilic Isosteres of a π-π Stacking Interaction: New Inhibitors of the Bcl-2-Bak Protein-Protein Interaction.
AID1690773Induction of apoptosis in human MOLT-4 cells assessed as early apoptotic cells at 10 nM measured after 48 hrs by Alexa Fluor 647-Annexin V/propidium iodide staining based flow cytometry (Rvb = 1.5 to 1.7%)
AID1296621Cell cycle arrest in human HCT116 p53-/- cells assessed as accumulation at 2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID431401Inhibition of recombinant His6-tagged Bcl-XL expressed in Escherichia coli BL21 (DE3) and Flu-Bak peptide interaction by fluorescence polarization assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID1851855Inhibition of MCL-1 (unknown origin) by fluorescence polarization competition assay2022RSC medicinal chemistry, Aug-17, Volume: 13, Issue:8
Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads.
AID654461Binding affinity to Bcl-22012European journal of medicinal chemistry, May, Volume: 51Structure-activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction.
AID1545373Oral bioavailability in dog2019European journal of medicinal chemistry, Apr-01, Volume: 167Clinical candidates modulating protein-protein interactions: The fragment-based experience.
AID539959Inhibition of Bcl-XL2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors.
AID515601Inhibition of GST-tagged Bcl-xl/FITC-conjugated PUMA interaction by fluorescence polarisation assay2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
Synthesis and biological activities of new di- and trimeric quinoline derivatives.
AID687158Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID652722Induction of Mcl-1-mediated apoptosis in doxycyclin-stimulated human HeLa cells overexpressing Bad3SA at 1 uM after 12 hrs by Hoechst staining2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.
AID277486Displacement of Bax-derived peptide from Bcl2 by fluorescence polarization assay2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID277495Inhibition of tumor growth in SUDHL4 xenografted SCID mouse at 50 mg/kg, ip twice daily relative to control2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID1690778Induction of apoptosis in human MOLT-4 cells assessed as late apoptotic cells at 100 nM measured after 48 hrs by Alexa Fluor 647-Annexin V/propidium iodide staining based flow cytometry (Rvb = 1.1 to 1.4%)
AID728146Cytotoxicity against human NCI-H1963 cells assessed as growth inhibition after 4 days by WST assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
A potent and highly efficacious Bcl-2/Bcl-xL inhibitor.
AID389267Oral bioavailability in Sprague-Dawley rat at 5 mg/kg2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
AID710850Binding affinity to Bcl-XL2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
An anthraquinone scaffold for putative, two-face Bim BH3 α-helix mimic.
AID1353867Cytotoxicity against human NCI-H929 cells assessed as reduction in cell viability after 24 hrs by MTT assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.
AID628401Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 E129H mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID1690781Induction of apoptosis in human MOLT-4 cells assessed as early apoptotic cells at 100 nM measured after 48 hrs in presence of pan-caspase inhibitor QVD by Alexa Fluor 647-Annexin V/propidium iodide staining based flow cytometry (Rvb = 1.5 to 1.7%)
AID1504724Inhibition of His-tagged MCL1 (unknown origin)/5-carboxyfluorescein-labeled Bid (unknown origin) protein protein interaction after 1 hr by fluorescence polarization assay2017Journal of natural products, 12-22, Volume: 80, Issue:12
(+)- and (-)-Ecarlottones, Uncommon Chalconoids from Fissistigma latifolium with Pro-Apoptotic Activity.
AID389260Displacement of fluorescein labeled BAD peptide from Bcl-XL by fluorescence polarization assay2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
AID640092Cytotoxicity against human Raji cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
AID687165Ratio of IC50 for human K562/HHT300 cells to IC50 for human K562 cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1483466Binding affinity to Bcl2A1 (unknown origin)2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.
AID1178316Binding affinity to Bcl-b (unknown origin)2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Biased and unbiased strategies to identify biologically active small molecules.
AID431385Cytotoxicity against human NALM6 cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID1690774Induction of apoptosis in human MOLT-4 cells assessed as late apoptotic cells at 10 nM measured after 48 hrs by Alexa Fluor 647-Annexin V/propidium iodide staining based flow cytometry (Rvb = 1.1 to 1.4%)
AID756765Binding affinity to human GST-tagged Bcl-Xl by fluorescence polarization assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
AID277496Displacement of Bad-derived peptide from Bcl-xL by FPA in presence of 10% human serum2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID1893747Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
Novel Bcl-2 Inhibitors Selectively Disrupt the Autophagy-Specific Bcl-2-Beclin 1 Protein-Protein Interaction.
AID1690772Induction of apoptosis in human MOLT-4 cells assessed as viable cells at 10 nM measured after 48 hrs by Alexa Fluor 647-Annexin V/propidium iodide staining based flow cytometry (Rvb = 97.1 to 97.3%)
AID1483462Inhibition of Bcl-2 (unknown origin)2017Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3
Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.
AID1690775Induction of apoptosis in human MOLT-4 cells assessed as necrotic cells at 10 nM measured after 48 hrs by Alexa Fluor 647-Annexin V/propidium iodide staining based flow cytometry (Rvb = 0.3 to 0.4%)
AID1851856Inhibition of BCL-2 (unknown origin) by fluorescence polarization competition assay2022RSC medicinal chemistry, Aug-17, Volume: 13, Issue:8
Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads.
AID330779Cytotoxicity against BCL2 overexpressing human KB cells transfected with luciferase siRNA assessed as annexin 5 uptake at 0.5 uM after 72 hrs by flow cytometry2007Proceedings of the National Academy of Sciences of the United States of America, Dec-04, Volume: 104, Issue:49
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
AID515599Inhibition of GST-tagged Bcl-xl/FITC-conjugated Bid interaction by fluorescence polarisation assay2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
Synthesis and biological activities of new di- and trimeric quinoline derivatives.
AID694156Antiproliferative activity against human NCI-H1963 cells after 4 days by WST8 assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID330750Induction of apoptosis in mouse Eu-Myc cells overexpressing MCL1 assessed as inhibition of colony formation at 1 uM2007Proceedings of the National Academy of Sciences of the United States of America, Dec-04, Volume: 104, Issue:49
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
AID277500Reversal of cytokine withdrawal protection in IL3 dependent Bcl-xL overexpressing mouse FL5.12 cells in presence of 3% FBS2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID701516Inhibition of GST-tagged recombinant Bfl1 interaction with biotinylated Bim peptide by ELISA based competitive binding assay2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID756752Binding affinity to human GST-tagged Bcl-Xl assessed as dissociation rate by surface plasmon resonance assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
AID330757Cytotoxicity in human KB cells overexpressing BCL2 at 0.5 uM2007Proceedings of the National Academy of Sciences of the United States of America, Dec-04, Volume: 104, Issue:49
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
AID1178318Binding affinity to bovine beta-casein A12014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Biased and unbiased strategies to identify biologically active small molecules.
AID1690760Toxicity in human platelet assessed as reduction in cell viability measured after 48 hrs by MTS assay
AID694169Induction of cell death in human NCI-H146 cells after 24 hrs by trypan blue assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID1296622Cell cycle arrest in human HCT116 p53+/+ cells assessed as accumulation at G2/M phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric method (Rvb = 26%)2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1599454Inhibition of Bcl2 (unknown origin)2019European journal of medicinal chemistry, Sep-01, Volume: 177The chemical biology of apoptosis: Revisited after 17 years.
AID431391Cytotoxicity against human MCF7 cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID1320548Selectivity index, ratio of Ki for Bcl-2 (unknown origin) to Ki for MCL-1 (unknown origin)2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID671073Inhibition of Bcl22012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein.
AID1352853Cytotoxicity against human HL60/VCR cells assessed as reduction in cell viability at 1 to 2 uM by CellTiter-Glo luminescent assay relative to control2018European journal of medicinal chemistry, Feb-25, Volume: 146Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
AID628396Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A93V mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID526645Binding affinity to Bcl-xl2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
AID652711Induction of apoptosis in human HeLa cells assessed as caspase activation at 1 uM by Hoechst staining2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.
AID640032Cytotoxicity against human HCT116 cells expressing Bcl-xL, Bcl-2 and Mcl-1 after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
AID701532Induction of apoptosis in human BP3 cells at 10 uM incubated for 24 hrs by Annexin V and propidium iodide staining based FACS method2012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID683531Inhibition of Bcl2-BAK interaction after 1 hr by surface plasmon resonance assay2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
Lipophilic Isosteres of a π-π Stacking Interaction: New Inhibitors of the Bcl-2-Bak Protein-Protein Interaction.
AID694172Induction of apoptosis in human NCI-H146 cells assessed as PARP cleavage after 24 hrs by Western blot analysis2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID1545355Inhibition of BCL-2 (unknown origin) in presence of 10% human serum incubated for 15 mins by fluorescence polarization assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Clinical candidates modulating protein-protein interactions: The fragment-based experience.
AID277501Inhibition of tumor growth in SUDHL4 xenografted SCID mouse at 50 mg/kg, ip in combination with etoposide at 20 mg/kg, ip2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID277497Reversal of cytokine withdrawal protection in IL3 dependent Bcl2 overexpressing mouse FL5.12 cells in presence of bovine gelatin2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID687161Ratio of IC50 for human HL60/ADR cells to IC50 for human HL60 cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID628395Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Wild type Bcl-2-like protein 1 expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID1296637Induction of apoptosis in human DMS53 cells harboring p53 mutant assessed as cytochrome c release at 5 to 10 uM after 12 hrs by immunoblotting method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID587009Binding affinity to Bcl-Xl assessed as association rate constant by surface plasmon resonance assay2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
AID1599455Inhibition of Bcl-xL (unknown origin)2019European journal of medicinal chemistry, Sep-01, Volume: 177The chemical biology of apoptosis: Revisited after 17 years.
AID277491Inhibition of cell growth in human RS11380 cells overexpressing Bcl2 in presence of 3% FBS2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID1816656Inhibition of GST tagged human/mouse chimeric MCL-1 by surface plasmon resonance assay
AID1388438Inhibition of Bcl2 (unknown origin)2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.
AID1545356Inhibition of BCL-XL (unknown origin) in presence of 10% human serum incubated for 15 mins by fluorescence polarization assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Clinical candidates modulating protein-protein interactions: The fragment-based experience.
AID1353866Cytotoxicity against human RS4:11 cells assessed as reduction in cell viability after 24 hrs by MTT assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Dual inhibitors of the pro-survival proteins Bcl-2 and Mcl-1 derived from natural compound meiogynin A.
AID671074Inhibition of Bcl-w2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein.
AID675724Growth inhibition of human NCI-H1417 cells after 4 days by WST8 assay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold.
AID628403Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 L130G mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID1891304Antiproliferative activity against cisplatin-resistant human MCF7-CR cells assessed as reduction in cell viability after 24 hrs by MTT assay2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67New synthetic phenylquinazoline derivatives induce apoptosis by targeting the pro-survival members of the BCL-2 family.
AID1224379Displacement of fluorescein-labeled BID from His-tagged MCL-1 (unknown origin) after 1 hr by fluorescence polarization assay2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Endiandric acid analogues from Beilschmiedia ferruginea as dual inhibitors of Bcl-xL/Bak and Mcl-1/Bid interactions.
AID1178313Binding affinity to Bcl-xL (unknown origin)2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Biased and unbiased strategies to identify biologically active small molecules.
AID687166Ratio of IC50 for human CCRF-CEM/C2 cells IC50 for human CCRF-CEM cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1893748Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
Novel Bcl-2 Inhibitors Selectively Disrupt the Autophagy-Specific Bcl-2-Beclin 1 Protein-Protein Interaction.
AID587092Cytotoxicity against mouse mcl-1 deficient MEF cells after 24 hrs by Cell titer glo assay in presence of 10% serum2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
AID1296608Cell cycle arrest in human HCT116 p53+/+ cells assessed as accumulation at 2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID756757Binding affinity to human GST-tagged Bcl-Xl by surface plasmon resonance assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
AID1690779Induction of apoptosis in human MOLT-4 cells assessed as necrotic cells at 100 nM measured after 48 hrs by Alexa Fluor 647-Annexin V/propidium iodide staining based flow cytometry (Rvb = 0.3 to 0.4%)
AID1388441Antiproliferative activity against human MOLT4 cells in presence of 10% human serum2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.
AID1296611Inhibition of MDM2-p53 interaction in human HCT116 p53+/+ cells assessed as upregulation of p53 expression at 5 to 10 uM after 12 hrs by immunoblotting method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID526651Induction of apoptosis in human CLL cells2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
AID756747Cytotoxicity against bax and bak deficient MFF assessed as cell viability after overnight incubation by celltiter-blue assay in presence of 1% FBS2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
AID1690777Induction of apoptosis in human MOLT-4 cells assessed as early apoptotic cells at 100 nM measured after 48 hrs by Alexa Fluor 647-Annexin V/propidium iodide staining based flow cytometry (Rvb = 1.5 to 1.7%)
AID727592Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance analysis2013ACS medicinal chemistry letters, Feb-14, Volume: 4, Issue:2
The role of the acidity of N-heteroaryl sulfonamides as inhibitors of bcl-2 family protein-protein interactions.
AID277490Inhibition of cell growth in human DoHH2 cells overexpressing Bcl2 in presence of 10% HS2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID628350Binding affinity for GST-tagged human BCL2A1 expressed in Escherichia coli BL21 cells2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID687163Ratio of IC50 for doxorubicin-resistant human HL60 cells to IC50 for human HL60 cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1816653Inhibition of GST tagged human BCL-XL deltaC25 by surface plasmon resonance assay
AID687159Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID728129Cytotoxicity against human NCI-H1417 cells assessed as growth inhibition after 4 days by WST assay2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
A potent and highly efficacious Bcl-2/Bcl-xL inhibitor.
AID1320545Inhibition of 5-FAM-Bid peptide binding to Bcl-XL (unknown origin) by fluorescence polarization assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID277493Inhibition of cell growth in human SUDHL4 cells overexpressing Bcl2 in presence of 3% FBS2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID756754Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
AID1545369Oral bioavailability in rat2019European journal of medicinal chemistry, Apr-01, Volume: 167Clinical candidates modulating protein-protein interactions: The fragment-based experience.
AID628488Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 G196A mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID1599456Inhibition of Bcl-w (unknown origin)2019European journal of medicinal chemistry, Sep-01, Volume: 177The chemical biology of apoptosis: Revisited after 17 years.
AID1320552Growth inhibition of human SKOV3 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID1296613Inhibition of MDM2-p53 interaction in human HCT116 p53+/+ cells assessed as upregulation of p21 expression at 5 to 10 uM after 12 hrs by immunoblotting method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID1504723Inhibition of His-tagged Bcl-xL (unknown origin)/5-carboxyfluorescein-labeled Bak (unknown origin) protein protein interaction after 1 hr by fluorescence polarization assay2017Journal of natural products, 12-22, Volume: 80, Issue:12
(+)- and (-)-Ecarlottones, Uncommon Chalconoids from Fissistigma latifolium with Pro-Apoptotic Activity.
AID675722Binding affinity to N-terminus 8X His-tagged human Mcl1 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold.
AID694157Antagonist activity at recombinant Bcl2 assessed as restoration of BIM BH3-induced cytochrome c release in mitochondria isolated from MDA-MB-231 cells after 1 hr by Western blot analysis2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID654459Binding affinity to Mcl-12012European journal of medicinal chemistry, May, Volume: 51Structure-activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction.
AID652720Induction of Bcl-xL-mediated apoptosis in doxycyclin-stimulated human HeLa cells overexpressing Noxa at 1 uM after 12 hrs by Hoechst staining2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study.
AID1545368Half life in rat2019European journal of medicinal chemistry, Apr-01, Volume: 167Clinical candidates modulating protein-protein interactions: The fragment-based experience.
AID1320549Growth inhibition of human HL60 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID389264Cytotoxicity against human NCI-H146 cells assessed as cell viability after 48 hrs in presence of 10% human serum2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
AID628486Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A142T mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID587010Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
AID1677975Inhibition of N-His6-tagged human AspH (315-755) expressed in Escherichia coli BL21 (DE3) using high 10 uM hFX-CP as substrate mixture with 10 uM 2OG, 100 uM L-ascorbic acid and 2 uM FAS incubated for 35 mins by MS analysis2020Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20
Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.
AID628485Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 A142G mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID1545372Half life in dog2019European journal of medicinal chemistry, Apr-01, Volume: 167Clinical candidates modulating protein-protein interactions: The fragment-based experience.
AID694162Antagonist activity at recombinant Bcl-XL assessed as restoration of BIM BH3-induced Smac protein release in mitochondria isolated from MDA-MB-231 cells at 0.03 to 1 uM after 1 hr by Western blot analysis2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID587088Cytotoxicity against mouse MEF cells expressing mcl-1 fl/fl at 10 uM after 24 hrs by Cell titer glo assay in presence of 10% fetal bovine serum2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
AID330761Cytotoxicity against BCL2 overexpressing human KB cells transfected with MCL1 siRNA assessed as annexin 5 reactivity at 0.5 uM after 72 hrs by flow cytometry2007Proceedings of the National Academy of Sciences of the United States of America, Dec-04, Volume: 104, Issue:49
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
AID389263Cytotoxicity against IL3-dependent mouse FL5.12 cells overexpressing human Bcl-XL assessed as cell viability after 24 hrs by MTS assay in absence of serum2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
AID694158Antagonist activity at recombinant Bcl2 assessed as restoration of BIM BH3-induced Smac protein release in mitochondria isolated from MDA-MB-231 cells after 1 hr by Western blot analysis2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID756766Cytotoxicity against mcl-1 deficient MFF assessed as cell viability after overnight incubation by celltiter-blue assay in presence of 1% FBS2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
AID431386Cytotoxicity against human REH cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID431389Cytotoxicity against mouse Hepa-1c1c7 cells after 48 hrs by cell titer-blue assay2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID628405Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 delta136T mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID1352852Cytotoxicity against human Raji cells assessed as reduction in cell viability at 1 to 2 uM by CellTiter-Glo luminescent assay relative to control2018European journal of medicinal chemistry, Feb-25, Volume: 146Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
AID1320553Growth inhibition of human NCI-H23 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID640031Cytotoxicity against human MDA-MB-435 cells expressing Bcl-xL, Bcl-2 and Mcl-1 at 100 ug/ml after 72 hrs by MTT assay relative to control2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
AID1816658Cytotoxicity against MCL deficient mouse embryonic fibroblast cells assessed as reduction in cell viability in presence of 1 % fetal calf serum measured after 24 hrs by propidium iodide staining based flow cytometric analysis
AID1320550Growth inhibition of human U266 cells after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID628397Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 E96G mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID277499Reversal of cytokine withdrawal protection in IL3 dependent Bcl-xL overexpressing mouse FL5.12 cells in presence of bovine gelatin2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID587091Cytotoxicity against mouse MEF cells expressing mcl-1 fl/fl after 24 hrs by Cell titer glo assay in presence of 10% serum2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
AID756748Cytotoxicity against wild type MFF assessed as cell viability after overnight incubation by celltiter-blue assay in presence of 10% FBS2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
AID587007Binding affinity to Bcl-Xl2011Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
AID1320547Selectivity index, ratio of Ki for Bcl-2 (unknown origin) to Ki for Bcl-XL (unknown origin)2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and activity evaluation of selective inhibitors of anti-apoptotic Bcl-2 proteins: The effects on the selectivity of the P1 pockets in the active sites.
AID1296612Inhibition of MDM2-p53 interaction in human HCT116 p53+/+ cells assessed as upregulation of MDM2 expression at 5 to 10 uM after 12 hrs by immunoblotting method2016Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7
Bcl-2/MDM2 Dual Inhibitors Based on Universal Pyramid-Like α-Helical Mimetics.
AID640027Binding affinity to Bcl-xL by competitive fluorescence polarization assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
AID687168Ratio of IC50 for human CCRF-CEM/VLB100 cells IC50 for human CCRF-CEM cells2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1816651Inhibition of GST tagged human BCL-XL deltaC25 using biotin-DLRPEIRIAQELRIZIGDEFNETYTRR as substrate incubated for 40 mins followed by substrate addition measured after 4 hrs by AlphaSCREEN assay
AID628400Displacement of BODIPY-Bak conjugated peptide from GST-tagged human Bcl-2-like protein 1 Y101H mutant expressed in Escherichia coli BL21 cells at 10 uM after 3 hrs by fluorescence polarization competition assay2011Bioorganic & medicinal chemistry letters, Sep-01, Volume: 21, Issue:17
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
AID701259Induction of apoptosis in human NCI-H146 cells assessed as cell viability at 30 to 100 nM after 24 hrs by trypan blue exclusion assay2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.
AID701261Induction of apoptosis in human NCI-H146 cells assessed as cell viability after 24 hrs by trypan blue exclusion assay2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.
AID515600Inhibition of GST-tagged Bcl-xl/FITC-conjugated Bim interaction by fluorescence polarisation assay2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
Synthesis and biological activities of new di- and trimeric quinoline derivatives.
AID1178314Binding affinity to Bcl-2 (unknown origin)2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Biased and unbiased strategies to identify biologically active small molecules.
AID515597Inhibition of GST-tagged Bcl-xl/FITC-conjugated Bax interaction by fluorescence polarisation assay2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
Synthesis and biological activities of new di- and trimeric quinoline derivatives.
AID1690783Induction of apoptosis in human MOLT-4 cells assessed as necrotic cells at 100 nM measured after 48 hrs in presence of pan-caspase inhibitor QVD by Alexa Fluor 647-Annexin V/propidium iodide staining based flow cytometry (Rvb = 0.3 to 0.4%)
AID1816655Inhibition of human BCL-W deltaC23 C29S/A128E mutant by surface plasmon resonance assay
AID1293716Inhibition of human Bcl-XL deltaC24 mutant at 25 degC by surface plasmon resonance method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity.
AID694154Antiproliferative activity against human NCI-H146 cells after 4 days by WST8 assay2012Journal of medicinal chemistry, Jul-12, Volume: 55, Issue:13
Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
AID756756Binding affinity to Bcl-w (unknown origin) by surface plasmon resonance assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
AID277498Reversal of cytokine withdrawal protection in IL3 dependent Bcl2 overexpressing mouse FL5.12 cells in presence of 3% FBS2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID330778Cytotoxicity against BCL2 overexpressing human KB cells transfected with luciferase siRNA assessed as propidium iodide uptake at 0.5 uM after 72 hrs by flow cytometry2007Proceedings of the National Academy of Sciences of the United States of America, Dec-04, Volume: 104, Issue:49
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
AID701527Binding affinity to Bcl22012European journal of medicinal chemistry, Nov, Volume: 57Synthesis and biological activities of polyquinoline derivatives: new Bcl-2 family protein modulators.
AID756755Binding affinity to human/mouse chimeric Mcl-1 by surface plasmon resonance assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346193Human BCL2, apoptosis regulator (B-cell lymphoma 2 (Bcl-2) protein family)2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID1346232Human Bcl-2-like 1 (B-cell lymphoma 2 (Bcl-2) protein family)2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID1346192Human Bcl-2-like 2 (B-cell lymphoma 2 (Bcl-2) protein family)2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID1798080Fluorescence Polarization Assay and FL5.12 Cellular Assay from Article 10.1021/jm061152t: \\Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.\\2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
AID1800239SPR Directy Binding Assay (Biacore 4000) from Article 10.1038/nchembio.1246: \\Structure-guided design of a selective BCL-X(L) inhibitor.\\2013Nature chemical biology, Jun, Volume: 9, Issue:6
Structure-guided design of a selective BCL-X(L) inhibitor.
AID1800237AlphaScreen Assay (AS) from Article 10.1038/nchembio.1246: \\Structure-guided design of a selective BCL-X(L) inhibitor.\\2013Nature chemical biology, Jun, Volume: 9, Issue:6
Structure-guided design of a selective BCL-X(L) inhibitor.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2007Cell death and differentiation, Sep, Volume: 14, Issue:9
Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (629)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's101 (16.06)29.6817
2010's468 (74.40)24.3611
2020's60 (9.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.28 (24.57)
Research Supply Index6.45 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index59.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews44 (6.96%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other588 (93.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		2.51206-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
butyric acid
Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.. butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.. butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.		2.5720fatty acid 4:0;
straight-chain saturated fatty acid		human urinary metabolite;
Mycoplasma genitalium metabolite
methane
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed). methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).		2.1510alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas
lactic acid
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.		2.53202-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
melatonin
[no description available]		2.610acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		4.6780pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
phosphorylcholine
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.. phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.		2.6320phosphocholinesallergen;
epitope;
hapten;
human metabolite;
mouse metabolite
pteridines
[no description available]		2.0810azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
pteridines
spermidine
[no description available]		2.4110polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
catechin
[no description available]		2.0310hydroxyflavan
hoe 33342
BXI-72: structure in first source		3.6320bibenzimidazole;
N-methylpiperazine		fluorochrome
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		2.5420benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
benserazide
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.. benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.		2.4110carbohydrazide;
catechols;
primary alcohol;
primary amino compound		antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
berberine
[no description available]		2.5420alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound		antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker
bisbenzimidazole
Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.		2.0610bibenzimidazole;
N-methylpiperazine		anthelminthic drug;
fluorochrome
celecoxib
[no description available]		2.7830organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.5120aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
erythrosine
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.		2.1310
carbonyl cyanide p-trifluoromethoxyphenylhydrazone
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.		2.4620aromatic ether;
hydrazone;
nitrile;
organofluorine compound		ATP synthase inhibitor;
geroprotector;
ionophore
fluorouracil
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.		2.5420nucleobase analogue;
organofluorine compound		antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic
gossypol
Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.		12.43270
ha14-1
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia		9.67801-benzopyran
hydroxychloroquine
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.		2.0710aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug
indoprofen
Indoprofen: A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p21). indoprofen : A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(1-oxo-1,3-dihydroisoindol-2-yl)phenyl group. Initially used as an anti-inflammatory and analgesic, it was withdrawn from the market due to causing severe gastrointestinal bleeding. It has been subsequently found to increase production of the survival motor neuron protein.		2.4110gamma-lactam;
isoindoles;
monocarboxylic acid		EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source		2.5720chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
vitamin k 3
Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.		2.41101,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		2.9330guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
methadone
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.		2.0610benzenes;
diarylmethane;
ketone;
tertiary amino compound
nocodazole
[no description available]		2.0810aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes		antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		2.4620dihydroxyanthraquinoneanalgesic;
antineoplastic agent
entinostat
[no description available]		2.0610benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
naftopidil
[no description available]		7.2510piperazines
nalidixic acid
[no description available]		2.41101,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic		antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor
pd 98059
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.		2.0510aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
4-phenylbutyric acid
4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.		2.2510monocarboxylic acidantineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug
ag 1879
3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor		2.110aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine		beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector
sb 202190
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase		2.0510imidazoles;
organofluorine compound;
phenols;
pyridines		apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
suberoyl bis-hydroxamic acid
suberoyl bis-hydroxamic acid: antineoplastic, Histone Deacetylase inhibitor		2.0510hydroxamic acid
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		8.1750dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
temozolomide
[no description available]		7.7930imidazotetrazine;
monocarboxylic acid amide;
triazene derivative		alkylating agent;
antineoplastic agent;
prodrug
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		7.111011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
cysteine
[no description available]		2.4110cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid		EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite
biguanides
Biguanides: Derivatives of biguanide (the structure formula HN(C(NH)NH2)2) that are primarily used as oral HYPOGLYCEMIC AGENTS for the treatment of DIABETES MELLITUS, TYPE 2 and PREDIABETES.. biguanides : A class of oral hypoglycemic drugs used for diabetes mellitus or prediabetes treatment. They have a structure based on the 2-carbamimidoylguanidine skeleton.		7.1310guanidines
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		2.5420alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
serine
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.		2.4110L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
4-nitroquinoline-1-oxide
4-nitroquinoline N-oxide : A quinoline N-oxide carrying a nitro substituent at position 4.		2.1110C-nitro compound;
quinoline N-oxide		carcinogenic agent
glutamine
Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.		2.1110amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
lysine
Lysine: An essential amino acid. It is often added to animal feed.. lysine : A diamino acid that is caproic (hexanoic) acid bearing two amino substituents at positions 2 and 6.. L-lysine : An L-alpha-amino acid; the L-isomer of lysine.		2.5220aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
vincristine
[no description available]		2.4620acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid		antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
carbostyril
Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.		2.1110monohydroxyquinoline;
quinolone		bacterial xenobiotic metabolite
adenosine monophosphate
Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.		2.3110adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
leucine
Leucine: An essential branched-chain amino acid important for hemoglobin formation.. leucine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group.		2.1310amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
methionine
Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.		2.4110aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid		antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		2.4110amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
egtazic acid
Egtazic Acid: A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.. ethylene glycol bis(2-aminoethyl)tetraacetic acid : A diether that is ethylene glycol in which the hydrogens of the hydroxy groups have been replaced by 2-[bis(carboxymethyl)amino]ethyl group respectively.		2.0610diether;
tertiary amino compound;
tetracarboxylic acid		chelator
gliotoxin
Gliotoxin: A fungal toxin produced by various species of Trichoderma, Gladiocladium fimbriatum, Aspergillus fumigatus, and Penicillium. It is used as an immunosuppressive agent.. gliotoxin : A pyrazinoindole with a disulfide bridge spanning a dioxo-substituted pyrazine ring; mycotoxin produced by several species of fungi.		2.4110dipeptide;
organic disulfide;
organic heterotetracyclic compound;
pyrazinoindole		antifungal agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
immunosuppressive agent;
mycotoxin;
proteasome inhibitor
cytarabine
[no description available]		3.4670beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		2.4110L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
threonine
Threonine: An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.. threonine : An alpha-amino acid in which one of the hydrogens attached to the alpha-carbon of glycine is substituted by a 1-hydroxyethyl group.		2.4110amino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
alizarin
[no description available]		2.0710dihydroxyanthraquinonechromophore;
dye;
plant metabolite
tryptophan
Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.		2.4110erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
isoleucine
Isoleucine: An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.. isoleucine : A 2-amino-3-methylpentanoic acid having either (2R,3R)- or (2S,3S)-configuration.. L-isoleucine : The L-enantiomer of isoleucine.		2.4110aspartate family amino acid;
isoleucine;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		2.2510benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
acenaphthenequinone
acenaphthoquinone : An orthoquinone that is the 1,2-dioxo derivative of acenaphthene.		2.0810orthoquinoneschain carrier;
epitope
vitamin k5
vitamin k5: RN given refers to parent cpd		2.4110naphthols
rotenone
Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.		2.1310organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
2-phenylphenol
2-phenylphenol: RN given refers to parent cpd; structure. biphenyl-2-ol : A member of the class of hydroxybiphenyls that is biphenyl substituted by a hydroxy group at position 2. It is generally used as a post-harvest fungicide for citrus fruits.		2.0510hydroxybiphenylsantifungal agrochemical;
environmental food contaminant
quinoxalines
quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.		2.0710mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
4-phenylphenol
4-phenylphenol: RN given refers to cpd without isomeric designation. biphenyl-4-ol : A member of the class of hydroxybiphenyls that is biphenyl carrying a hydroxy group at position 4.		3.3110hydroxybiphenyls
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		7.42310pyrrole;
secondary amine
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		2.5420mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
phenformin
Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.		2.1310biguanidesantineoplastic agent;
geroprotector;
hypoglycemic agent
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		2.9840azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
acridines
Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.		2.0810acridines;
mancude organic heterotricyclic parent;
polycyclic heteroarene		genotoxin
indazoles
Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.		2.7930indazole
benzoxazoles
1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.		2.11101,3-benzoxazoles;
mancude organic heterobicyclic parent
isoxazoles
Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.		2.1510isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thiazoles
[no description available]		4.29501,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		4130diazine;
pyrazines		Daphnia magna metabolite
azacitidine
Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.		3.9240N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
indirubin
[no description available]		7.1310
fructose-1,6-diphosphate
beta-D-fructofuranose 1,6-bisphosphate : A D-fructofuranose 1,6-bisphosphate with a beta-configuration at the anomeric position.		2.4110D-fructofuranose 1,6-bisphosphatemouse metabolite
thymoquinone
thymoquinone: constituent of cedarwood; can cause dermatitis; structure. thymoquinone : A member of the class of 1,4-benzoquinones that is 1,4-bezoquinone in which the hydrogens at positions 2 and 5 are replaced by methyl and isopropyl groups, respectively. It is a natural compound isolated from Nigella sativa which has demonstrated promising chemotherapeutic activity.		7.15101,4-benzoquinonesadjuvant;
anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
cardioprotective agent;
plant metabolite
2,4-pyridinedicarboxylic acid
lutidinic acid : A pyridinedicarboxylic acid carrying carboxy groups at positions 2 and 4.		2.2510pyridinedicarboxylic acid
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		2.4920
thiazolidines
Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.		2.2110thiazolidine
hematoxylin
Hematoxylin: A dye obtained from the heartwood of logwood (Haematoxylon campechianum Linn., Leguminosae) used as a stain in microscopy and in the manufacture of ink.		2.4110organic heterotetracyclic compound;
oxacycle;
polyphenol;
tertiary alcohol		histological dye;
plant metabolite
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.110furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
syringic acid
syringic acid: RN given refers to parent cpd; structure in third source. syringic acid : A dimethoxybenzene that is 3,5-dimethyl ether derivative of gallic acid.		2.4110benzoic acids;
dimethoxybenzene;
phenols		plant metabolite
decamethonium dibromide
[no description available]		3.1910
3-hydroxyflavone
3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.		2.4110flavonols;
monohydroxyflavone
diphenylamine
Diphenylamine: In humans it may be irritating to mucous membranes. Methemoglobinemia has been produced experimentally. In veterinary use, it is one of active ingredients in topical agents for prevention and treatment of screwworm infestation. An indicator in tests for nitrate poisoning.. diphenylamine : An aromatic amine containing two phenyl substituents. It has been used as a fungicide for the treatment of superficial scald in apples and pears, but is no longer approved for this purpose within the European Union.		2.8130aromatic amine;
bridged diphenyl fungicide;
secondary amino compound		antifungal agrochemical;
antioxidant;
carotogenesis inhibitor;
EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitor;
ferroptosis inhibitor;
radical scavenger
ethylnitrosourea
Ethylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-ethyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by ethyl and nitroso groups.		2.0310N-nitrosoureasalkylating agent;
carcinogenic agent;
genotoxin;
mutagen
deoxycytidine
[no description available]		2.7930pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
arsenic trioxide
Arsenic Trioxide: An inorganic compound with the chemical formula As2O3 that is used for the treatment of ACUTE PROMYELOCYTIC LEUKEMIA in patients who have relapsed from, or are resistant to, conventional drug therapy.		7.0710
glycyrrhizic acid
glycyrrhizinic acid : A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid.		2.1110enone;
glucosiduronic acid;
pentacyclic triterpenoid;
tricarboxylic acid;
triterpenoid saponin		EC 3.4.21.5 (thrombin) inhibitor;
plant metabolite
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		4.2750beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
helium
Helium: A noble gas with the atomic symbol He, atomic number 2, and atomic weight 4.003. It is a colorless, odorless, tasteless gas that is not combustible and does not support combustion. It was first detected in the sun and is now obtained from natural gas. Medically it is used as a diluent for other gases, being especially useful with oxygen in the treatment of certain cases of respiratory obstruction, and as a vehicle for general anesthetics.		2.0710monoatomic helium;
noble gas atom;
s-block element atom		food packaging gas
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		9.4160delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
aluminum sulfate
aluminium sulfate (anhydrous) : An aluminium sulfate that contains no water of crystallisation.		2.1510aluminium sulfate
clodronic acid
Clodronic Acid: A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.. clodronic acid : An organochlorine compound that is methylene chloride in which both hydrogens are replaced by phosphonic acid groups. It inhibits bone resorption and soft tissue calcification, and is used (often as the disodium salt tetrahydrate) as an adjunct in the treatment of severe hypercalcaemia associated with malignancy, and in the management of osteolytic lesions and bone pain associated with skeletal metastases.		2.21101,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound		antineoplastic agent;
bone density conservation agent
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		3.2150aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		2.1510glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		6.02130taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
etoposide
[no description available]		5.12160beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
staurosporine
[no description available]		2.0710indolocarbazole alkaloid;
organic heterooctacyclic compound		apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		7.7930organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
irinotecan
[no description available]		3.8930carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		2.0610adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
epigallocatechin gallate
epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.		2.5120flavans;
gallate ester;
polyphenol		antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite
5-hydroxyflavone
[no description available]		2.4110flavones
5,6,7,8-tetrahydro-1-naphthol
5,6,7,8-tetrahydro-1-naphthol : 1-naphthol hydrogenated at C-5, -6, -7 and -8.		3.6520tetralins
fluorodeoxyglucose f18
Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)		2.72202-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose
zoledronic acid
Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.		7.06101,1-bis(phosphonic acid);
imidazoles		bone density conservation agent
epicatechin
(-)-epicatechin : A catechin with (2R,3R)-configuration.		2.5120catechin;
polyphenol		antioxidant
gallocatechol
(-)-epigallocatechin : A flavan-3,3',4',5,5',7-hexol having (2R,3R)-configuration.		2.0310catechin;
flavan-3,3',4',5,5',7-hexol		antioxidant;
food component;
plant metabolite
6-hydroxyflavone
6-hydroxyflavone: antioxidant; structure in first source		2.4110hydroxyflavonoid
picropodophyllin
picropodophyllin: isolated from American May apple (Podophyllum); inhibits IGF-I autophosphorylation without interfering with tyrosine kinase activity. picropodophyllotoxin : An organic heterotetracyclic compound that has a furonaphthodioxole skeleton bearing 3,4,5-trimethoxyphenyl and hydroxy substituents.		2.110furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antineoplastic agent;
insulin-like growth factor receptor 1 antagonist;
plant metabolite;
tyrosine kinase inhibitor
alkannin
alkannin: a naphthazarin used to promote wound healing, from the plant Alkanna tinctoria; RN given refers to (S)-isomer; structure		2.4110hydroxy-1,4-naphthoquinone
3-deazaneplanocin
3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist		2.0610
bendamustine hydrochloride
[no description available]		2.5220
norcantharidin
norcantharidin: structure given in first source; RN given refers to cpds without isomeric designation		2.8230furofuran
mafosfamide
mafosfamide: RN given refers to cis-(+-)-isomer		3.0410
epicatechin gallate
epicatechin gallate: a steroid 5alpha-reductase inhibitor; RN given refers to the (cis)-isomer; structure given in first source; isolated from green tea. (-)-epicatechin-3-O-gallate : A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3R)-hydroxy group of epicatechin. A natural product found in Parapiptadenia rigida.		2.0310catechin;
gallate ester;
polyphenol		EC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
metabolite
triptolide
[no description available]		2.0710diterpenoid;
epoxide;
gamma-lactam;
organic heteroheptacyclic compound		antispermatogenic agent;
plant metabolite
cafestol
[no description available]		7.110diterpenoid;
furans;
organic heteropentacyclic compound;
primary alcohol;
tertiary alcohol		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
plant metabolite
tamibarotene
tamibarotene: has retinoid-binding activity. tamibarotene : A dicarboxylic acid monoamide resulting from the condensation of one of the carboxy groups of terephthalic acid with the amino group of 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-amine.		3.1510dicarboxylic acid monoamide;
retinoid;
tetralins		antineoplastic agent;
retinoic acid receptor alpha/beta agonist
deoxyglucose
Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.		3.1950
neoeriocitrin
neoeriocitrin: protects against autophagy-inhibiting effects of okadaic acid; isolated from Drynariae rhizome; structure in first source. neoeriocitrin : A flavanone glycoside that is eriodictyol substituted by a 2-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage.		2.41104'-hydroxyflavanones;
disaccharide derivative;
flavanone glycoside;
neohesperidoside;
trihydroxyflavanone		plant metabolite
oxymatrine
oxysophoridine: an alkaloid isolated from Sophra alope; structure in first source		2.4110alkaloid;
tertiary amine oxide
astragaloside a
[no description available]		2.2110
celastrol
[no description available]		7.0710monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
imatinib mesylate
imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.		8.6790methanesulfonate saltanticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor
gefitinib
[no description available]		2.0310aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
e 64
E 64: cysteine protease inhibitor of microbial origin, which inhibits cathepsin B (EC 3.4.22.1) and cathepsin L (EC 3.4.22.-)		2.1310dicarboxylic acid monoamide;
epoxy monocarboxylic acid;
guanidines;
L-leucine derivative;
zwitterion		antimalarial;
antiparasitic agent;
protease inhibitor
clitocine
clitocine: structure & RN given in first source		7.110N-glycosyl compound
bh 3
BH 3: RN given refers to parent cpd		2.9940
proline
Proline: A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons.. proline : An alpha-amino acid that is pyrrolidine bearing a carboxy substituent at position 2.		2.4110amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
docetaxel anhydrous
Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.		2.9940secondary alpha-hydroxy ketone;
tetracyclic diterpenoid		antimalarial;
antineoplastic agent;
photosensitizing agent
perifosine
[no description available]		2.6320ammonium betaine;
phospholipid		EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
lonafarnib
lonafarnib: inhibitor of farnesyl protein transferase. lonafarnib : A 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide that has R configuration. It is used as oral farnesyltransferase inhibitor.		3.15104-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamideantineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
tipifarnib
[no description available]		3.1510imidazoles;
monochlorobenzenes;
primary amino compound;
quinolone		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
cyc 202
seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.		2.44202,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
6-n-tridecylsalicylic acid
6-n-tridecylsalicylic acid: structure given in first source		2.1310hydroxybenzoic acid
methylselenic acid
methylseleninic acid : An organoselenium compound that is seleninic acid in which the hydrogen attached to selenium is replaced by a methyl group.		2.0710one-carbon compound;
organoselenium compound		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
human xenobiotic metabolite
tanshinone ii a
tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source		2.4110abietane diterpenoid
angiotensin ii
Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).		2.2510amino acid zwitterion;
angiotensin II		human metabolite
erlotinib hydrochloride
[no description available]		2.0610hydrochloride;
terminal acetylenic compound		antineoplastic agent;
protein kinase inhibitor
2-(5-Chlorobenzo[b]thiophen-3-yl)acetic acid
[no description available]		3.19101-benzothiophenes
lapatinib
[no description available]		2.0810furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
sorafenib
[no description available]		4.7890(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
alpha-(trichloromethyl)-4-pyridineethanol
alpha-(trichloromethyl)-4-pyridineethanol: activates caspase-3		3.1210pyridines
gossypol acetic acid
[no description available]		4.9660
blastmycin
blastmycin: structure		2.0310amidobenzoic acid
anisomycin
Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.. (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.		2.610monohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic		anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor
homoharringtonine
Homoharringtonine: Semisynthetic derivative of harringtonine that acts as a protein synthesis inhibitor and induces APOPTOSIS in tumor cells. It is used in the treatment of MYELOID LEUKEMIA, CHRONIC.. omacetaxine mepesuccinate : A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.		2.4820alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol		anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor
bortezomib
[no description available]		5.3160amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
calcein am
calcein AM: a non-fluorescent compound cleaved to a fluorescent compound by non-specific intracellular esterases. calcein am : An organic heteropentacyclic compound that is calcein in which all four carboxy group hydrogens have been substituted by (acetyloxy)methoxy groups and the hyrodgens of the two hydroxy groups have been substituted by acetyl groups. It is a a non-fluorescent probe cleaved to a fluorescent probe by non-specific intracellular esterases.		2.13102-benzofurans;
acetate ester;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
xanthene dye		fluorochrome
nsc 23766
[no description available]		3.1310aminopyrimidine;
aminoquinoline;
primary amino compound;
secondary amino compound;
tertiary amino compound		antiviral agent;
apoptosis inducer;
EC 3.6.5.2 (small monomeric GTPase) inhibitor;
muscarinic antagonist
leupeptins
Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.		2.0510
carboplatin
[no description available]		3.6890
inositol 1,4,5-trisphosphate
Inositol 1,4,5-Trisphosphate: Intracellular messenger formed by the action of phospholipase C on phosphatidylinositol 4,5-bisphosphate, which is one of the phospholipids that make up the cell membrane. Inositol 1,4,5-trisphosphate is released into the cytoplasm where it releases calcium ions from internal stores within the cell's endoplasmic reticulum. These calcium ions stimulate the activity of B kinase or calmodulin.		2.0710myo-inositol trisphosphatemouse metabolite
taxifolin
(+)-taxifolin : A taxifolin that has (2R,3R)-configuration.		2.4110taxifolinmetabolite
micheliolide
micheliolide: has antineoplastic activity; structure in first source		2.4110sesquiterpene lactone
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		2.4110antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
tretinoin
Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.		2.3110retinoic acid;
vitamin A		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		7.6320resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
ferulic acid
ferulate : A monocarboxylic acid anion obtained by the deprotonation of the carboxy group of ferulic acid.		2.4110ferulic acidsanti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
MALDI matrix material;
plant metabolite
thapsigargin
Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.		2.4820butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone		calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
epothilone b
[no description available]		7.1310epothilone;
epoxide		antineoplastic agent;
apoptosis inducer;
microtubule-stabilising agent
bms 214662
7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source. BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.		3.1510benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes		antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor
epothilone a
Epothilones: A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).		2.1310epothilone;
epoxide		antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator
apogossypol
apogossypol: structure in first source		3.620
purvalanol a
6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;		2.2510purvalanol
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		3.1750actinomycinmutagen
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		7.4520L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
benzyloxycarbonylleucyl-leucyl-leucine aldehyde
benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.		2.0510amino aldehyde;
carbamate ester;
tripeptide		proteasome inhibitor
shikonin
shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities		2.4110hydroxy-1,4-naphthoquinone
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		2.5220stilbene
s 1033
[no description available]		2.5220(trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
triiodothyronine, reverse
[no description available]		2.41103,3',5'-triiodothyronine;
amino acid zwitterion
6-[(2-fluorophenyl)methyl]-2,4-dimethyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone
[no description available]		2.4110organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
fludarabine
[no description available]		9.2750purine nucleoside
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		3.1140aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
umi-77
UMI-77: an Mcl-1 inhibitor; structure in first source		3.6920
nbd 556
[no description available]		3.1310
thioguanine anhydrous
Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.		2.05102-aminopurinesanticoronaviral agent;
antimetabolite;
antineoplastic agent
digoxin
Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.		2.4110cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester
[no description available]		2.0610
rtki cpd
RTKI cpd: preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors		2.0710
dasatinib
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).		2.5201,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor
verticillins
verticillins: 3 antibiotics isolated from imperfect fungus Verticillium: verticillin A, verticillin B (mono-3-hydroxymethyl analog of verticillin A), & verticillin C (differs from verticillin B in that 1 of dioxopiperazine rings has a trisulfide rather than a disulfide bridge; active against gram-positive bacteria & mycobacteria but not against gram-negative bacteria & fungi; RN given refers to cpd with unknown MF; structure (verticillins A & B))		2.3110
ovalbumin
Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.		2.1510
3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3h)-quinazolinone
3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone: a mitochondrial division inhibitor		2.110
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		2.830
5,6-dehydrokawain
5,6-dehydrokawain: from Alpinia speciosa rhizoma; RN given for cpd without isomeric designation; structure given in first source		2.15102-pyranones;
aromatic ether
sphingosine
sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.		3.1210sphing-4-eninehuman metabolite;
mouse metabolite
quercetin
[no description available]		8.9307-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
apigenin
Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.		2.4110trihydroxyflavoneantineoplastic agent;
metabolite
quercetin 3-o-glucopyranoside
quercetin 3-O-glucopyranoside: structure in first source. quercetin 3-O-beta-D-glucopyranoside : A quercetin O-glucoside that is quercetin with a beta-D-glucosyl residue attached at position 3. Isolated from Lepisorus contortus, it exhibits antineoplastic activityand has been found to decrease the rate of polymerization and sickling of red blood cells		2.4110beta-D-glucoside;
monosaccharide derivative;
quercetin O-glucoside;
tetrahydroxyflavone		antineoplastic agent;
antioxidant;
antipruritic drug;
bone density conservation agent;
geroprotector;
histamine antagonist;
osteogenesis regulator;
plant metabolite
cucurbitacin i
cucurbitacin I: toxic constituent in edible gourd; see also records for cucurbitacins & specific cucurbitacins. cucurbitacin I : A cucurbitacin that is 9,10,14-trimethyl-4,9-cyclo-9,10-secocholesta-2,5,23-triene substituted by hydroxy groups at positions 2, 16, 20 and 25 and oxo groups at positions 1, 11 and 22.		2.1110cucurbitacin;
tertiary alpha-hydroxy ketone		antineoplastic agent;
plant metabolite
fisetin
[no description available]		2.41103'-hydroxyflavonoid;
7-hydroxyflavonol;
tetrahydroxyflavone		anti-inflammatory agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
metabolite;
plant metabolite
myricetin
[no description available]		2.41107-hydroxyflavonol;
hexahydroxyflavone		antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite
scutellarein
scutellarein: aglycone of scutellarin from Scutellaria baicalensis; carthamidin is 2S isomer of scutellarein; do not confuse with isoscutellarein and/or isocarthamidin which are respective regioisomers, or with the scutelarin protein. scutellarein : Flavone substituted with hydroxy groups at C-4', -5, -6 and -7.		2.4110tetrahydroxyflavonemetabolite
wogonin
wogonin: structure in first source. wogonin : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.		2.4110dihydroxyflavone;
monomethoxyflavone		angiogenesis inhibitor;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
plant metabolite
polydatin
trans-piceid : A stilbenoid that is trans-resveratrol substituted at position 3 by a beta-D-glucosyl residue.		2.4110beta-D-glucoside;
monosaccharide derivative;
polyphenol;
stilbenoid		anti-arrhythmia drug;
antioxidant;
geroprotector;
hepatoprotective agent;
metabolite;
nephroprotective agent;
potassium channel modulator
iridin
iridin : A glycosyloxyisoflavone that is irigenin substituted by a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage.		2.41104'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative		plant metabolite
rottlerin
rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.		2.0510aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone		anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite
7-hydroxyflavone
7-hydroxyflavone : A hydroxyflavonoid in which the flavone nucleus is substituted at position 7 by a hydroxy group.		2.4110hydroxyflavonoid
isotretinoin
Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.		2.0510retinoic acidantineoplastic agent;
keratolytic drug;
teratogenic agent
sphingosine 1-phosphate
sphingosine 1-phosphate: RN given refers to (R-(R*,S*-(E)))-isomer; RN for cpd without isomeric designation not available 8/89. sphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1		3.1210sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent
sirolimus
Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.		4.5870antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
fenretinide
Fenretinide: A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.. 4-hydroxyphenyl retinamide : A retinoid obtained by formal condensation of the carboxy group of all-trans retinoic acid and the anilino group of 4-hydroxyaniline. Synthetic retinoid agonist. Antiproliferative, antioxidant and anticancer agent with a long half-life in vivo. Apoptotic effects appear to be mediated by a mechanism distinct from that of 'classical' retinoids.		8.1650monocarboxylic acid amide;
retinoid		antineoplastic agent;
antioxidant
N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide
N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide : A leucine derivative obtained by fpormal condensation of the secondary amino group of 5-({2,3-dichloro-4-[1-methyl-5-(piperidin-4-yl)-1H-pyrazol-3-yl]phenoxy}methyl)-2-furoic acid and the carboxy group of N-amidino-L-leucylglycine		3.1310D-leucine derivative;
dichlorobenzene;
furoic acid;
glycine derivative;
guanidines;
pyrazolylpiperidine
su 5402
SU 5402: structure given in first source. SU5402 : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 3-(2-carboxyethyl)-4-methyl-1H-pyrrol-2-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.		2.0810
su 9516
[no description available]		2.1510
dexmedetomidine
[no description available]		2.4110medetomidinealpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative
vinorelbine
[no description available]		2.110acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid		antineoplastic agent;
photosensitizing agent
kn 93
KN 93: reduces dopamine content in PC12h cells. KN-93 : A sulfonamide resulting from the formal condensation of p-methoxybenzenesulfonic acid with the anilino nitrogen of 2-(aminomethyl)-N-(2-hydroxyethyl)aniline in which the hydrogens of the primary amino group have been replaced by methyl and p-chlorocinnamyl groups. KN-93 is a selective inhibitor of Ca(2+)/calmodulin-dependent protein kinase II.		2.0710monochlorobenzenes;
monomethoxybenzene;
primary alcohol;
sulfonamide;
tertiary amino compound		EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor;
geroprotector
glycycoumarin
glycycoumarin: from the root of Glycyrrhizae Radix, acts as a potent antispasmodic through inhibition of phosphodiesterase 3; structure in first source. glycycoumarin : A member of the class of coumarins that is coumarin substituted by a hydroxy group at position 7, a methoxy group at position 5, a prenyl group at position 6 and a 2,4-dihydroxyphenyl group at position 3. Isolated from Glycyrrhiza uralensis, it exhibits antispasmodic activity.		7.1710aromatic ether;
coumarins;
resorcinols		antispasmodic drug;
plant metabolite
(E)-3-(2-Hydroxyphenyl)-2-propenal
[no description available]		2.4110cinnamaldehydes
casein kinase ii
Casein Kinase II: A ubiquitous casein kinase that is comprised of two distinct catalytic subunits and dimeric regulatory subunit. Casein kinase II has been shown to phosphorylate a large number of substrates, many of which are proteins involved in the regulation of gene expression.		2.1510
spd-304
SPD-304: structure in first source		3.1310
palbociclib
[no description available]		3.1510aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
fosbretabulin
fosbretabulin: a microtubule destabilizing agent isolated from Combretum caffrum; structure in first source		2.110
arsenic
Arsenic: A shiny gray element with atomic symbol As, atomic number 33, and atomic weight 75. It occurs throughout the universe, mostly in the form of metallic arsenides. Most forms are toxic. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), arsenic and certain arsenic compounds have been listed as known carcinogens. (From Merck Index, 11th ed)		7.0710metalloid atom;
pnictogen		micronutrient
sanglifehrin a
sanglifehrin A: binds cyclophilin A; isolated from Streptomyces; structure in first source		2.1110
bleomycin
[no description available]		2.2510bleomycinantineoplastic agent;
metabolite
vx680
[no description available]		7.1110N-arylpiperazine
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid: An inhibitor of anion conductance including band 3-mediated anion transport.		2.520
(-)-catechin-3-O-gallate
(-)-catechin-3-O-gallate : A gallate ester obtained by formal condensation of the carboxy group of gallic acid with the (3R)-hydroxy group of (-)-catechin.		2.4110flavans;
gallate ester;
polyphenol		metabolite
antimycin a
Antimycin A: An antibiotic substance produced by Streptomyces species. It inhibits mitochondrial respiration and may deplete cellular levels of ATP. Antimycin A1 has been used as a fungicide, insecticide, and miticide. (From Merck Index, 12th ed). antimycin A : A nine-membered bis-lactone having methyl substituents at the 2- and 6-positions, an n-hexyl substituent at the 8-position, an acyloxy substituent at the 7-position and an aroylamido substituent at the 3-position. It is produced by Streptomyces bacteria and has found commercial use as a fish poison.		3.1410amidobenzoic acid
bafilomycin a1
bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.		2.110cyclic hemiketal;
macrolide antibiotic;
oxanes		apoptosis inducer;
autophagy inhibitor;
bacterial metabolite;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
ferroptosis inhibitor;
fungicide;
potassium ionophore;
toxin
tanespimycin
CP 127374: analog of herbimycin A		2.03101,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor
beta-escin
[no description available]		2.2110
tubacin
tubacin: inhibits histone deacetylase 6; structure in first source		2.25101,3-oxazoles
sq-23377
Ionomycin: A divalent calcium ionophore that is widely used as a tool to investigate the role of intracellular calcium in cellular processes.. ionomycin : A very long-chain fatty acid that is docosa-10,16-dienoic acid which is substituted by methyl groups at positions 4, 6, 8, 12, 14, 18 and 20, by hydroxy groups at positions 11, 19 and 21, and by a (2',5-dimethyloctahydro-2,2'-bifuran-5-yl)ethanol group at position 21. An ionophore produced by Streptomyces conglobatus, it is used in research to raise the intracellular level of Ca(2+) and as a research tool to understand Ca(2+) transport across biological membranes.		2.4820cyclic ether;
enol;
polyunsaturated fatty acid;
very long-chain fatty acid		calcium ionophore;
metabolite
beta-elemene
beta-elemene: increases tumor cell immunogenicity by inducing, at least in part, elevated expression of heat shock protein 70 on tumor cell surface. beta-elemene : A sesquiterpene that consists of cyclohexane bearing methyl and vinyl substituents at position 1 as well as two isopropenyl substituents at positions 2 and 4.. (-)-beta-elemene : The (-)-enantiomer of beta-elemene that has (1S,2S,4R)-configuration.		2.4110beta-elemeneantineoplastic agent
pd 184352
2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source		2.0510aminobenzoic acid
belinostat
[no description available]		2.2510hydroxamic acid;
olefinic compound;
sulfonamide		antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
panobinostat
Panobinostat: An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.. panobinostat : A hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.		2.7630cinnamamides;
hydroxamic acid;
methylindole;
secondary amino compound		angiogenesis modulating agent;
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor
staurosporine
staurosporinium : Conjugate acid of staurosporine.		2.7930ammonium ion derivative
triacsin c
triacsin C: from Streptomyces No. 1228; structure given in first source; an acyl-CoA synthetase antagonist. triacsin C : A nitroso compound that is N-undecylnitrous hydrazide carrying double bonds at positions 1,2,4, and 7. It is a long-chain fatty acyl CoA synthetase inhibitor and interferes with lipid metabolism by inhibiting the de novo synthesis of glycerolipids and cholesterol esters.		3.1210hydrazone;
nitroso compound;
olefinic compound		antimalarial;
apoptosis inhibitor;
bacterial metabolite;
EC 3.1.1.64 (retinoid isomerohydrolase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
vasodilator agent
pd 0325901
mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).		2.8130difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound		antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
midostaurin
midostaurin : An organic heterooctacyclic compound that is the N-benzoyl derivative of staurosporine.		2.2510benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
gambogic acid
gambogic acid: RN given refers to (1R-(1alpha,1(Z),3abeta,5alpha,11beta,14aS*))-isomer		2.0710pyranoxanthonesmetabolite
pi103
PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce		2.4920aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
hki 272
[no description available]		2.1710nitrile;
quinolines		antineoplastic agent;
tyrosine kinase inhibitor
sepantronium
sepantronium: a survivin suppressant with antineoplastic activity. sepantronium : An organic cation that is 1-(2-methoxyethyl)-2-methyl-1H-naphtho[2,3-d]imidazole-4,9-dione in which the nitrogen at position 3 of the napthoimidazole moiety has been alkylated by a pyrazin-2-ylmethyl group.		2.5220organic cation
binimetinib
binimetinib : A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-fluorophenyl)nitrilo, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor (IC50= 12 nM). Approved by the FDA for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation in combination with encorafenib.		7.1710benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monofluorobenzenes;
secondary amino compound		antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
erucylphospho-n,n,n-trimethylpropylammonium
erucylphospho-N,N,N-trimethylpropylammonium: an antineoplastic agent		2.6620
wp1066
[no description available]		2.1110
np 031112
tideglusib: an NSAID and neuroprotective agent. tideglusib : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a naphthalen-1-yl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta) and has neuroprotective effects. Currently under clinical investigation for the treatment of Alzheimer's disease and progressive supranuclear palsy.		2.3110benzenes;
naphthalenes;
thiadiazolidine		anti-inflammatory agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent
bi 2536
[no description available]		2.0810
inno-406
[no description available]		7.0310biaryl
nutlin-3a
nutlin 3: an MDM2 antagonist; structure in first source		4.7890stilbenoid
danusertib
[no description available]		2.610piperazines
N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide
[no description available]		2.0510benzamides
pf 00299804
dacomitinib: a pan-ERBB inhibitor. dacomitinib : A member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin-1-yl)but-2-enoyl group.		2.1710enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
2,5-dimethylcelecoxib
2,5-dimethylcelecoxib: non-COX-2 inhibitory structural analog of celecoxib		2.1310
trametinib
[no description available]		2.5920acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly		anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
silvestrol
silvestrol: isolated from the fruit and twig of Aglaia silvestris. silvestrol : An organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.		2.0510dioxanes;
ether;
methyl ester;
organic heterotricyclic compound		antineoplastic agent;
metabolite
calcimycin
Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.		3.3560benzoxazole
dactolisib
dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.		2.4920imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		5.47230
meayamycin
meayamycin: inhibits pre-mRNA splicing; has antineoplastic activity; structure in first source		2.0810
buparlisib
NVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first source		2.110aminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
tg101209
[no description available]		2.0810N-alkylpiperazine;
N-arylpiperazine;
pyrimidines;
secondary amino compound;
sulfonamide		antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
nsc 23766
NSC 23766 trihydrochloride : A hydrochloride resulting from the formal reaction of NSC 23766 with 3 mol eq. of hydrogen chloride. An inhibitor of the signalling G-protein known as RAC1 (Ras-related C3 botulinum toxin substrate 1).. Rac1 inhibitor : Any inhibitor of Rac1.		2.0610hydrochlorideantiviral agent;
apoptosis inducer;
EC 3.6.5.2 (small monomeric GTPase) inhibitor;
muscarinic antagonist
sphingosine kinase
[no description available]		3.1210
thiostrepton
Thiostrepton: One of the CYCLIC PEPTIDES from Streptomyces that is active against gram-positive bacteria. In veterinary medicine, it has been used in mastitis caused by gram-negative organisms and in dermatologic disorders.. thiostrepton : A heterodetic cyclic peptide, in which the cyclisation step involves a formal lactonisation between the carboxy group of a quinaldic acid-based residue and a secondary alcohol. An antibiotic that inhibits bacterial protein synthesis. Also acts as an antitumor agent.		2.0510
plx 4720
PLX 4720: a B-Raf(V600E) kinase inhibitor; structure in first source		2.5220aromatic ketone;
difluorobenzene;
organochlorine compound;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
lcl161
[no description available]		2.11101,3-thiazoles;
aromatic ketone;
L-alanine derivative;
monofluorobenzenes;
N-acylpyrrolidine		antineoplastic agent;
apoptosis inducer
mln 8237
MLN 8237: an aurora kinase A inhibitor		2.610benzazepine
gdc 0449
HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity		2.0810benzamides;
monochlorobenzenes;
pyridines;
sulfone		antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent
marinopyrrole a
marinopyrrole A: antibiotic from a marine Streptomyces sp.; structure in first source. (-)-marinopyrrole A : A member of the class of pyrroles that is 1'H-1,3'-bipyrrole substituted by four chloro groups at positions 4, 4', 5 and 5' and two 2-hydroxybenzoyl moieties at positions 2 and 2'. It is isolated from Streptomyces sp.CNQ-418 and exhibits cytotoxic and antibacterial activities.		9.9860aromatic ketone;
organochlorine compound;
phenols;
pyrroles		antibacterial agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
marine metabolite
delanzomib
[no description available]		3.1510C-terminal boronic acid peptide;
phenylpyridine;
secondary alcohol;
threonine derivative		antineoplastic agent;
apoptosis inducer;
proteasome inhibitor
pci 32765
ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.		2.1110acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
sch772984
[no description available]		2.1710biaryl;
indazoles;
N-acylpiperazine;
N-alkylpyrrolidine;
N-arylpiperazine;
pyridines;
pyrimidines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary amino compound;
tertiary carboxamide		analgesic;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
quizartinib
[no description available]		3.5820benzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas		antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor
navitoclax
[no description available]		9.64510aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4h-chromene-3-carboxylate
ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: has antineoplastic activity; structure in first source		2.4620
incb-018424
[no description available]		2.8830nitrile;
pyrazoles;
pyrrolopyrimidine		antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
azd2014
vistusertib: potent and selective dual mTORC1 and mTORC2 inhibitor; structure in first source		2.1310
(5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
(5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol: a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity; structure in first source		2.8130benzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
mTOR inhibitor
plx4032
[no description available]		5.140aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide		antineoplastic agent;
B-Raf inhibitor
meiogynin a
meiogynin A: from the bark of Meiogyne cylindrocarpa; structure in first source		2.1310
elafin
Elafin: A secretory proteinase inhibitory protein that was initially purified from human SKIN. It is found in a variety mucosal secretions and is present at high levels in SPUTUM. Elafin may play a role in the innate immunity (IMMUNITY, INNATE) response of the LUNG.		2.0810
piperidines
Piperidines: A family of hexahydropyridines.		2.1110
6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone
ML-265: a small molecule activator of PKM2		2.4110organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
interleukin-8
Interleukin-8: A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells.		2.0610
3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline
[no description available]		2.4110benzenes;
sulfonamide
gx 15-070
obatoclax: a pan-Bcl-2 inhibitor potentially useful in treating mantle cell lymphoma		7.17240
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine
sapanisertib: an mTOR inhibitor		2.1110benzoxazole
dinaciclib
[no description available]		7.1310pyrazolopyrimidine
birinapant
birinapant: a Smac mimetic with antineoplastic activity		2.1510dipeptide
abt-199
venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.		9.36390aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine		antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
ipi-145
[no description available]		2.1110isoquinolines
spautin-1
[no description available]		2.610
sar405838
SAR405838: an inhibitor of the interaction of MDM2 and p53; has antineoplastic activity; structure in first source		2.1110
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		2.1710benzenes;
hydroxycoumarin;
methyl ketone
jy-1-106
JY-1-106: a BH3 alpha-helix mimetic that functions as a pan-Bcl-2 inhibitor; structure in first source		4.1920
pelabresib
CPI-0610: a bromodomain and extra-terminal protein inhibitor with antineoplastic activity; structure in first source		3.3110monochlorobenzenes;
organic heterotricyclic compound;
primary carboxamide		antineoplastic agent;
bromodomain-containing protein 4 inhibitor
azd1208
[no description available]		2.2110
a-1155463
A-1155463: a Bcl-X(L) inhibitor; structure in first source		3.6620
bm-1197
BM-1197: inhibits both Bcl-xL and Bcl-2; has antineoplastic activity		4.1920
ML355
ML355: 12-Lipoxygenase inhibitor. ML355 : A sulfonamide resulting from the formal condensation of the amino group of 2-aminobenzothiazole with the sulfo group of 4-[(2-hydroxy-3-methoxybenzyl)amino]benzenesulfonic acid. It is an inhibitor of 12-lipoxygenase, being developed by Veralox Therapeutics for the treatment of heparin-induced thrombocytopenia and thrombosis.		7.4110benzothiazoles;
monomethoxybenzene;
phenols;
secondary amino compound;
substituted aniline;
sulfonamide		EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
platelet aggregation inhibitor
a-1331852
A-1331852: a Bcl-X(L) inhibitor; structure in first source		4.4730
hirudin
Hirudin: A 65-residue polypeptide from LEECHES.		2.0710
cyclin d1
Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.		2.9940
oligomycins
Oligomycins: A closely related group of toxic substances elaborated by various strains of Streptomyces. They are 26-membered macrolides with lactone moieties and double bonds and inhibit various ATPases, causing uncoupling of phosphorylation from mitochondrial respiration. Used as tools in cytochemistry. Some specific oligomycins are RUTAMYCIN, peliomycin, and botrycidin (formerly venturicidin X).		2.0610
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor		2.4820
nitrophenols
Nitrophenols: PHENOLS carrying nitro group substituents.		14.765610
morroniside
morroniside: from Cornus officinalis; protects cultured human umbilical vein endothelial cells from damage by high ambient glucose; a component of cornel iridoid glycoside; structure in first source		2.610
oblimersen
oblimersen: targets the Bcl-2 oncogene good efficacy with low toxicity tumour regressions		6.0170
cyclosporine
Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).		8.1950
siomycin a
siomycin A: see also records for siomycin & siomycin D1		2.0510
folic acid
folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.		2.2510folic acids;
N-acyl-amino acid		human metabolite;
mouse metabolite;
nutrient
3-methyladenine
N3-methyladenine: structure in first source		2.110
dacarbazine
(E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.		2.7930dacarbazine
methylnitronitrosoguanidine
Methylnitronitrosoguanidine: A nitrosoguanidine derivative with potent mutagenic and carcinogenic properties.. N-methyl-N'-nitro-N-nitrosoguanidine : An N-nitroguanidine compound having nitroso and methyl substituents at the N'-position		2.0710nitroso compoundalkylating agent
apogossypolone
apogossypolone: has antineoplastic activity; structure in first source		3.3110
pp242
torkinib : A member of the class of pyrazolopyrimidines that is 1H-pyrazolo[3,4-d]pyrimidine substituted by isopropyl, 5-hydroxyindol-2-yl and amino groups at positions 1, 3 and 4 respectively. It is a potent inhibitor of mTOR and exhibits anti-cancer properties.		2.0710aromatic amine;
biaryl;
hydroxyindoles;
phenols;
primary amino compound;
pyrazolopyrimidine		antineoplastic agent;
mTOR inhibitor
4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one
[no description available]		2.0210
meayamycin b
meayamycin B: structure in first source		2.4920
pyrimidinones
Pyrimidinones: Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O.		2.5920
sc-2001
SC-2001: obatoclax derivative; structure in first source		2.1510
phenanthrenes
Phenanthrenes: POLYCYCLIC AROMATIC HYDROCARBONS composed of three fused BENZENE rings.. phenanthrenes : Any benzenoid aromatic compound that consists of a phenanthrene skeleton and its substituted derivatives thereof.		2.0710
ConditionIndicatedRelationship StrengthStudiesTrials
Germinoblastoma
[description not available]		05.9140
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		05.9140
Malignant Melanoma
[description not available]		05.47230
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		05.47230
Leucocythaemia
[description not available]		05140
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		010140
Benign Neoplasms
[description not available]		010.15490
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		010.15490
Carcinoma, Non-Small Cell Lung
[description not available]		05.09150
Cancer of Lung
[description not available]		05.86340
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		05.09150
Lung Neoplasms
Tumors or cancer of the LUNG.		05.86340
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		05.62260
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Breast Cancer
[description not available]		04.54220
Breast Neoplasms
Tumors or cancer of the human BREAST.		16.54220
Dysmyelopoietic Syndromes
[description not available]		02.8430
Myelodysplastic Syndromes
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.		02.8430
Androgen-Independent Prostatic Cancer
[description not available]		02.6620
Prostatic Neoplasms, Castration-Resistant
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.		02.6620
Myeloproliferative Disorders
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.		03.0540
Lung Adenocarcinoma
[description not available]		02.8330
Adenocarcinoma of Lung
A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.		02.8330
Benign Cerebellar Neoplasms
[description not available]		02.8230
Arachnoidal Cerebellar Sarcoma, Circumscribed
[description not available]		02.8230
Medulloblastoma
A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)		07.8230
Cancer of Colon
[description not available]		03.98110
Colonic Neoplasms
Tumors or cancer of the COLON.		03.98110
Colorectal Cancer
[description not available]		04.11140
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		04.11140
Acute Myelogenous Leukemia
[description not available]		07.65280
Leukemia, Myeloid, Acute
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.		07.65280
Anoxemia
[description not available]		03.0140
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		03.0140
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		02.9430
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		02.9430
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		07.5820
B-Cell Lymphoma
[description not available]		05.2970
Lymphoma, B-Cell
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.		05.2970
Silicosis
A form of pneumoconiosis resulting from inhalation of dust containing crystalline form of SILICON DIOXIDE, usually in the form of quartz. Amorphous silica is relatively nontoxic.		02.2510
Lymph Node Metastasis
[description not available]		02.5820
Invasiveness, Neoplasm
[description not available]		02.2510
Experimental Mammary Neoplasms
[description not available]		02.2510
Cancer of Ovary
[description not available]		04.13140
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		04.13140
EBV Infections
[description not available]		02.2510
Duncan Disease
[description not available]		02.2510
Lymphoproliferative Disorders
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.		07.2510
Epstein-Barr Virus Infections
Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).		02.2510
Ph 1 Chromosome
[description not available]		02.2510
Hepatocellular Carcinoma
[description not available]		03.9110
Cancer of Liver
[description not available]		05.16160
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		03.9110
Liver Neoplasms
Tumors or cancer of the LIVER.		05.16160
Hematologic Malignancies
[description not available]		04.2230
Hematologic Neoplasms
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.		04.2230
Diffuse Large B-Cell Lymphoma
[description not available]		05.0790
Lymphoma, Large B-Cell, Diffuse
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.		05.0790
Atherogenesis
[description not available]		02.3110
Alloxan Diabetes
[description not available]		02.3110
Diabetic Angiopathies
VASCULAR DISEASES that are associated with DIABETES MELLITUS.		02.5420
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		02.3110
Bladder Cancer
[description not available]		07.5920
Carcinoma, Anaplastic
[description not available]		02.5420
Urinary Bladder Neoplasms
Tumors or cancer of the URINARY BLADDER.		02.5920
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		07.5420
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		03.7730
Disease Exacerbation
[description not available]		02.8230
Adenocarcinoma, Basal Cell
[description not available]		03.0440
Infections, Plasmodium
[description not available]		02.3110
Metastase
[description not available]		02.8130
Cancer of Pancreas
[description not available]		03.3560
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		03.0440
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		02.3110
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		02.3110
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.8130
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		03.3560
Acute Lymphoid Leukemia
[description not available]		03.93120
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		03.93120
B-Cell Chronic Lymphocytic Leukemia
[description not available]		012.53330
Leukemia, Lymphocytic, Chronic, B-Cell
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.		07.53330
Autoimmune Lymphoproliferative Syndrome
Rare congenital lymphoid disorder due to mutations in certain Fas-Fas ligand pathway genes. Known causes include mutations in FAS, TNFSF6, NRAS, CASP8, and CASP10 proteins. Clinical features include LYMPHADENOPATHY; SPLENOMEGALY; and AUTOIMMUNITY.		02.5320
Thrombopenia
[description not available]		03.4670
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		03.4670
Deep Vein Thrombosis
[description not available]		02.1510
Venous Thrombosis
The formation or presence of a blood clot (THROMBUS) within a vein.		02.1510
Osteogenic Sarcoma
[description not available]		02.5320
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		07.5320
Carcinoma, Small Cell Lung
[description not available]		03.87110
Small Cell Lung Carcinoma
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).		03.87110
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		04.8370
Cancer of Pituitary
[description not available]		02.1510
Craniopharyngioma, Adamantinous
[description not available]		02.1510
Craniopharyngioma
A benign pituitary-region neoplasm that originates from Rathke's pouch. The two major histologic and clinical subtypes are adamantinous (or classical) craniopharyngioma and papillary craniopharyngioma. The adamantinous form presents in children and adolescents as an expanding cystic lesion in the pituitary region. The cystic cavity is filled with a black viscous substance and histologically the tumor is composed of adamantinomatous epithelium and areas of calcification and necrosis. Papillary craniopharyngiomas occur in adults, and histologically feature a squamous epithelium with papillations. (From Joynt, Clinical Neurology, 1998, Ch14, p50)		02.1510
Pituitary Neoplasms
Neoplasms which arise from or metastasize to the PITUITARY GLAND. The majority of pituitary neoplasms are adenomas, which are divided into non-secreting and secreting forms. Hormone producing forms are further classified by the type of hormone they secrete. Pituitary adenomas may also be characterized by their staining properties (see ADENOMA, BASOPHIL; ADENOMA, ACIDOPHIL; and ADENOMA, CHROMOPHOBE). Pituitary tumors may compress adjacent structures, including the HYPOTHALAMUS, several CRANIAL NERVES, and the OPTIC CHIASM. Chiasmal compression may result in bitemporal HEMIANOPSIA.		02.1510
Leukemia, Lymphoblastic, Acute, T Cell
[description not available]		03.3660
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.		03.3660
Cancer of Prostate
[description not available]		03.3360
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		03.3360
Disease Resistance
The capacity of an organism to defend itself against pathological processes or the agents of those processes. This most often involves innate immunity whereby the organism responds to pathogens in a generic way. The term disease resistance is used most frequently when referring to plants.		02.1710
Local Neoplasm Recurrence
[description not available]		03.0440
Adenocarcinoma Of Kidney
[description not available]		03.250
Cancer of Kidney
[description not available]		03.250
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.		03.250
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		03.250
Cirrhosis
[description not available]		02.1710
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		02.1710
Cirrhosis, Liver
[description not available]		02.2110
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		02.2110
Allergic Rhinitis
[description not available]		07.1710
Rhinitis, Allergic
An inflammation of the NASAL MUCOSA triggered by ALLERGENS.		02.1710
Eczema, Atopic
[description not available]		02.1710
Dermatitis, Atopic
A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.		02.1710
Astrocytoma, Grade IV
[description not available]		03.790
Glial Cell Tumors
[description not available]		03.82100
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		03.790
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		03.82100
Experimental Neoplasms
[description not available]		04.6130
Innate Inflammatory Response
[description not available]		02.5520
Hutchinson Gilford Progeria Syndrome
[description not available]		02.1710
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.5520
Progeria
An abnormal congenital condition, associated with defects in the LAMIN TYPE A gene, which is characterized by premature aging in children, where all the changes of cell senescence occur. It is manifested by premature graying; hair loss; hearing loss (DEAFNESS); cataracts (CATARACT); ARTHRITIS; OSTEOPOROSIS; DIABETES MELLITUS; atrophy of subcutaneous fat; skeletal hypoplasia; elevated urinary HYALURONIC ACID; and accelerated ATHEROSCLEROSIS. Many affected individuals develop malignant tumors, especially SARCOMA.		02.1710
Benign Neoplasms, Brain
[description not available]		03.0340
Brain Neoplasms
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.		03.0340
Bacterial Pneumonia
[description not available]		02.2110
Pneumonia, Bacterial
Inflammation of the lung parenchyma that is caused by bacterial infections.		02.2110
Autoimmune Diabetes
[description not available]		02.5220
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		02.2110
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		02.5220
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		02.2110
Injury, Myocardial Reperfusion
[description not available]		02.2110
Epithelial Ovarian Cancer
[description not available]		02.2110
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.		02.2110
Hepatoblastoma
A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)		04.3870
Carcinoma, Epidermoid
[description not available]		03.680
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		03.680
Coagulation Disorders, Blood
[description not available]		02.0810
Blood Coagulation Disorders
Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.		02.0810
Rhabdomyosarcoma 2
[description not available]		02.0810
Rhabdomyosarcoma, Alveolar
A form of RHABDOMYOSARCOMA occurring mainly in adolescents and young adults, affecting muscles of the extremities, trunk, orbital region, etc. It is extremely malignant, metastasizing widely at an early stage. Few cures have been achieved and the prognosis is poor. Alveolar refers to its microscopic appearance simulating the cells of the respiratory alveolus. (Holland et al., Cancer Medicine, 3d ed, p2188)		02.0810
Kahler Disease
[description not available]		03.93120
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		03.93120
Rhabdomyosarcoma
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)		07.0810
Granulocytic Leukemia
[description not available]		02.7630
Leukemia, Myeloid
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.		02.7630
Cancer of Cervix
[description not available]		02.110
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		02.110
Cystadenocarcinoma, Serous
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)		02.1110
Cancer of Head
[description not available]		04.150
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		04.150
Cancer of Skin
[description not available]		03.1750
Skin Neoplasms
Tumors or cancer of the SKIN.		03.1750
ATLL
[description not available]		02.7730
Leukemia-Lymphoma, Adult T-Cell
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.		02.7730
Bone Cancer
[description not available]		02.5120
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.5120
Chondrosarcoma
A slowly growing malignant neoplasm derived from cartilage cells, occurring most frequently in pelvic bones or near the ends of long bones, in middle-aged and old people. Most chondrosarcomas arise de novo, but some may develop in a preexisting benign cartilaginous lesion or in patients with ENCHONDROMATOSIS. (Stedman, 25th ed)		02.4920
Libman-Sacks Disease
[description not available]		02.1110
Lupus Erythematosus, Systemic
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.		02.1110
Genome Instability
[description not available]		02.1110
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		03.4570
Cells, Neoplasm Circulating
[description not available]		02.1110
Lymphocytopenia
[description not available]		02.4920
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		07.1110
Lymphopenia
Reduction in the number of lymphocytes.		02.4920
Familial Waldenstrom's Macroglobulinaemia
[description not available]		02.1310
Waldenstrom Macroglobulinemia
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.		02.1310
Cholangiocellular Carcinoma
[description not available]		02.4920
Bile Duct Cancer
[description not available]		02.4920
Bile Duct Neoplasms
Tumors or cancer of the BILE DUCTS.		02.4920
Cholangiocarcinoma
A malignant tumor arising from the epithelium of the BILE DUCTS.		02.4920
Cancer of Mouth
[description not available]		02.8130
Mouth Neoplasms
Tumors or cancer of the MOUTH.		02.8130
Carcinoma, Transitional Cell
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.		02.1310
B16 Melanoma
[description not available]		02.4820
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.7630
Blast Phase
[description not available]		02.4920
Granulocytic Leukemia, Chronic
[description not available]		03.6790
Blast Crisis
An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.		02.4920
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.		03.6790
Carcinoma, Mucoepidermoid
A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)		02.1110
Cancer of Stomach
[description not available]		03.7130
Stomach Neoplasms
Tumors or cancer of the STOMACH.		03.7130
Cancer of the Thyroid
[description not available]		02.5420
Thyroid Neoplasms
Tumors or cancer of the THYROID GLAND.		02.5420
Carcinoma, Neuroendocrine
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)		02.1310
Carcinoma, Squamous Cell of Head and Neck
[description not available]		02.5320
Squamous Cell Carcinoma of Head and Neck
The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.		02.5320
Leiomyosarcoma, Epithelioid
[description not available]		02.1310
Cancer of the Uterus
[description not available]		02.1310
Leiomyosarcoma
A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)		02.1310
Retroperitoneal Neoplasms
New abnormal growth of tissue in the RETROPERITONEAL SPACE.		02.1310
Soft Tissue Neoplasms
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.		02.1310
Uterine Neoplasms
Tumors or cancer of the UTERUS.		02.1310
Chondrosarcoma, Mesenchymal
A rare aggressive variant of chondrosarcoma, characterized by a biphasic histologic pattern of small compact cells intermixed with islands of cartilaginous matrix. Mesenchymal chondrosarcomas have a predilection for flat bones; long tubular bones are rarely affected. They tend to occur in the younger age group and are highly metastatic. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1456)		02.1310
Brill-Symmers Disease
[description not available]		02.1510
Lymphoma, Follicular
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.		02.1510
Asthma, Bronchial
[description not available]		02.1510
Asthma
A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).		02.1510
Neurilemoma
[description not available]		02.1510
Neurilemmoma
A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)		02.1510
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
[description not available]		03.8840
Lymphoma, Mantle-Cell
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).		03.8840
Erythremia
[description not available]		02.7430
Polycythemia Vera
A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.		02.7430
Cutaneous T-Cell Lymphoma
[description not available]		02.0510
Lymphoma, T-Cell, Cutaneous
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.		02.0510
Adjuvant Arthritis
[description not available]		02.4620
Delayed Hypersensitivity
[description not available]		02.0510
Glomerulonephritis, Lupus
[description not available]		02.0510
Lupus Nephritis
Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).		02.0510
Granuloma, Hodgkin
[description not available]		02.4620
Hodgkin Disease
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.		02.4620
Bone Loss, Osteoclastic
[description not available]		02.0510
Gastrointestinal Stromal Neoplasm
[description not available]		02.0610
Gastrointestinal Stromal Tumors
All tumors in the GASTROINTESTINAL TRACT arising from mesenchymal cells (MESODERM) except those of smooth muscle cells (LEIOMYOMA) or Schwann cells (SCHWANNOMA).		02.0610
Schistosoma japonicum Infection
[description not available]		02.4720
Schistosoma mansoni Infection
[description not available]		02.4720
Schistosomiasis mansoni
Schistosomiasis caused by Schistosoma mansoni. It is endemic in Africa, the Middle East, South America, and the Caribbean and affects mainly the bowel, spleen, and liver.		02.4720
Hairy Cell Leukemia
[description not available]		02.9810
Leukemia, Hairy Cell
A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of hairy or flagellated cells in the blood and bone marrow.		02.9810
Mesothelioma
A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)		02.0610
Chromosome Deletion
Actual loss of portion of a chromosome.		02.0710
17p11.2 Monosomy
[description not available]		02.0710
Smith-Magenis Syndrome
Complex neurobehavioral disorder characterized by distinctive facial features (FACIES), developmental delay and INTELLECTUAL DISABILITY. Behavioral phenotypes include sleep disturbance, maladaptive, self-injurious and attention-seeking behaviors. The sleep disturbance is linked to an abnormal circadian secretion pattern of MELATONIN. The syndrome is associated with de novo deletion or mutation and HAPLOINSUFFICIENCY of the retinoic acid-induced 1 protein on chromosome 17p11.2.		02.0710
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		02.0610
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		02.0610
Acute Biphenotypic Leukemia
[description not available]		02.0610
Leukemia, Biphenotypic, Acute
An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.		02.0610
T-Cell Lymphoma
[description not available]		02.0710
Lymphoma, T-Cell
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.		02.0710
Cancer, Radiation-Induced
[description not available]		02.0710
Cancer of the Thymus
[description not available]		02.0710
Cancer Syndromes, Hereditary
[description not available]		02.0710
Thymus Neoplasms
Tumors or cancer of the THYMUS GLAND.		02.0710
Bone Marrow Failure
[description not available]		02.0710
Anemia, Hypoplastic
[description not available]		02.0710
Bone Marrow Diseases
Diseases involving the BONE MARROW.		02.0710
Marchiafava-Micheli Syndrome
[description not available]		02.0710
Bone Marrow Failure Disorders
Inherited or acquired diseases characterized by insufficient and/or dysplastic blood cells.		02.0710
Anemia, Aplastic
A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.		02.0710
Hemoglobinuria, Paroxysmal
A condition characterized by the recurrence of HEMOGLOBINURIA caused by intravascular HEMOLYSIS. In cases occurring upon cold exposure (paroxysmal cold hemoglobinuria), usually after infections, there is a circulating antibody which is also a cold hemolysin. In cases occurring during or after sleep (paroxysmal nocturnal hemoglobinuria), the clonal hematopoietic stem cells exhibit a global deficiency of cell membrane proteins.		02.0710
Diabetes Mellitus, Adult-Onset
[description not available]		02.0710
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.0710
Canine Diseases
[description not available]		02.0710
African Lymphoma
[description not available]		02.0710
Burkitt Lymphoma
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.		02.0710
Cerebral Ischemia
[description not available]		02.0710
Brain Ischemia
Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.		02.0710
Bleeding
[description not available]		02.0710
Hemorrhage
Bleeding or escape of blood from a vessel.		02.0710
Electron Transport Chain Deficiencies, Mitochondrial
[description not available]		02.0710
Mitochondrial Diseases
Diseases caused by abnormal function of the MITOCHONDRIA. They may be caused by mutations, acquired or inherited, in mitochondrial DNA or in nuclear genes that code for mitochondrial components. They may also be the result of acquired mitochondria dysfunction due to adverse effects of drugs, infections, or other environmental causes.		02.0710
Graft-Versus-Host Disease
[description not available]		02.0710
Graft vs Host Disease
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.		02.0710
B-Cell Leukemia
[description not available]		02.0710
Chromosomal Translocation
[description not available]		02.0710
Cafe-au-Lait Spots with Pulmonic Stenosis
[description not available]		02.4820
Neurofibromatosis 1
An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS).		02.4820
Metabolic Acidosis
[description not available]		02.0710
Acidosis
A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.		02.0710
Genito-urinary Cancer
[description not available]		0310
Urogenital Neoplasms
Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.		0310
Weight Reduction
[description not available]		02.0810
Weight Loss
Decrease in existing BODY WEIGHT.		02.0810
Neoplasms, Nerve Sheath
[description not available]		02.0810
Nerve Sheath Neoplasms
Neoplasms which arise from nerve sheaths formed by SCHWANN CELLS in the PERIPHERAL NERVOUS SYSTEM or by OLIGODENDROCYTES in the CENTRAL NERVOUS SYSTEM. Malignant peripheral nerve sheath tumors, NEUROFIBROMA, and NEURILEMMOMA are relatively common tumors in this category.		02.0810
Carcinoma, Oat Cell
[description not available]		03.8640
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		03.8640
Leukemia, Lymphocytic, T Cell
[description not available]		02.0310
Leukemia, T-Cell
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.		02.0310
Acute Disease
Disease having a short and relatively severe course.		02.0310